AUTHOR INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.
Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Abidi, S. M., 927, 963
Abrass, C. K., 11
Abreo, K., 325
Adams, P. L., 552
Agarwal, R., 682
Agodoa, L. Y. C., 1, 349, 507
Aguiari, G., 880
Ahlmén, J., 709
Akikusa, B., 1158
Alcazar, J. M., 1018
Alegre, R., 52
Alem, A., 941
Alexander, S. R., 567
Alfrey, C. P., 59
Alkhunaizi, A. M., 970
Allen, A. C., 1049
Al Masri, A. N., 434
Al-Mohaya, S., 1142
Alper, S. L., 1190
Alpers, C. E., 11, 658
Alphonse, J.-C., 633
Alter, M. J., 356
Al-Wakeel, J., 1142
Amoroso, A., 857
Anders, H.-J., 379, 4:E3
Anderson, J. E., 647
Anderson, S. C., 647
Andreoli, S. P., 814
Andreucci, M., 851
Ansari, N., 5:E3
Aparicio, M., 5:E4
Appel, G. B., 954
Applegarth, D., 4:E5
Archie, M., 872
Arcocha, V., 1:E3
Armistead, N., 97
Arrobas, M., 892
Arruda, J. A. L., 1033
Asfoura, J., 2:E8
Atsumi, K., 287
Au, T.-c., 6:E4
Aucouturier, P., 954
Augello, G., 880

Babrow, A. S., 688
Badzek, L. A., 688
Baggio, B., 105, 807
Bailey, E. M., 1049
Bailie, G. R., 111, 1187, 6:E3
Bairaktari, E., 1100
Balakrishnan, R., 1164
Balcke, P., 702
Baldamus, C. A., 3:E3
Balletta, M. M., 851
Bamonti-Catena, F., 492
Bang, B. K., 73
Bankl, H., 702
Baran, D., 2:E4
Barbieri, G., 702
Barendregt, J. M., 1115
Barolo, S., 1071
Barr, W. H., 389
Barratt, J., 1049
Batlle, D., 450
Bazzato, G., 105
Beathard, G. A., 910
Beck, G., 142
Becker, B. A., 369
Beger, H. G., 304
Behr, S. R., 633
Belanger, S., 1131
Belenfant, X., 840
Bello, E., 1018
Benedetti, F., 555
Benedetti, G., 746
Bengtsson, B.-Å., 709
Benigni, A., 746
Bennett, W. M., 970
Ben-Yehuda, A., 161
Berfield, A. K., 11
Bergelin, R. O., 675
Bernardini, J., 927, 1136
Bertorini, T. E., 966
Berutti, S., 1071
Besarab, A., 977
Best, J. H., 829
Birk, P. E., 374
Bistrian, B. R., 172
Biswas, P., 782
Bitter, D. C., 647
Black, N. A., 1107
Bleyer, A. J., 694
Bloembergen, W. E., 1, 507
Blomley, M. J. K., 754
Blondin, J., 198
Bøe, I.-M., 541
Boevé, E. R., 761
Bolton, W. K., 1177
Bonfante, L., 105
Bosch, J. P., 2:E6
Bowden, D. W., 294
Brenner, B., 253
Breslau, N. A., 369
Brewer, E. D., 205, 518, 667
Brickel, H. M., 920
Briefel, G. R., 647
Brost, B. C., 917
Brown, W. S., 1122
Bruijn, J. A., 166
Bruzzi, I., 746
Bryant, R. E., 790
Buccianti, G., 492
Buck, K. S., 1049
Buka, S., 253
Burema, J. H. G. A., 1115
Burg, M., 434
Burjak, K., 872
Burke, J. F., Jr., 150
Burke, S. K., 694
Butterly, D. W., 970
Butty, H., 2:E8

Cai, Y., 880
Calissi, P. T., 3:E4
Calviño, J., 1:E3
Campanini, M., 857
Campos, A. P., 52
Canavese, C., 1071
Cantwell-Gab, K., 675
Caplin, N. J., 4:E7
Cappelli, G., 880
Caps, M. T., 675
Caramelo, C., 3:E5, 1018
Caravaca, F., 892
Carroll, C. E., 349
Casado, S., 1018
Casper, E. S., 555
Castillo, A. A., 2:E6
Cattran, D. C., 1026, 1174
Chagnac, A., 82
Chahin, J., 458
Chan, D. T. M., 318
Chan, J. C. N., 1064
Chan, L., 301
Chan, S., 172
Chandrakantan, A., 6:E8
Chang, B. G., 441
Chang, Y. S., 73
Charytan, C., 170
Chatoth, D. K., 617
Chau, K. F., 535
Chaudhry, A., 133
Cherdkiadtikul, T., 886, 5:E5
Chertow, G. M., 193
Cheung, A. K., 349
Chi, H. S., 312

Choi, E. J., 73
Chuawatana, D., 1147
Ciccone, G., 1071
Clark, W. R., 87
Coe, F. L., 398
Collins, B., 128
Colombi, F., 267
Coma, D., 746
Combe, C., 4:E3, 5:E4
Combet, S., 383
Como, G., 492
Conlon, P. J., 970
Cooke, C. R., 899
Cortese, F., 2:E8
Cosyns, J.-P., 383, 1011
Crabtree, J. E., 1049
Crone, M., 1:E4
Cruickshank, M., 6:E6
Cruz, D. N., 920
Curhan, G. C., 398
Curtoni, E. S., 1071

D'Agati, V. D., 441, 954
Dall'Omo, A. M., 1071
Danesh, F. R., 450, 563
Daugirdas, J., 142
Davidson, R. C., 675
Davis, C. L., 11, 658
Davis, C. P., 786
Dawood, M., 728
De Broe, M. E., 1171
De Fijter, J. W., 166
De Jong, P. E., 6:E5
Delgado, R. G., 1018
Del Prete, D., 105
Del Senno, L., 880
DeMayo, F. J., 598
Demigné, C., 633
Deminière, C., 5:E4
De Nicola, L., 851
De Paoli Vitali, E., 880
Depner, T. A., 63, 142
Devuyst, O., 383
De Water, R., 761
Diamond, L. H., 208
Diaz-Buxo, J. A., 523
Dick, C. D., 1080
Dikman, S., 4:E7
Dillon, M., 694
Dixit, A., 498
Dohi, K., 772
Domínguez-Gil, B., 52
Dominic, S. S., 325
Donley, V., 498
Donnelly, S., 947
Doyle, M., 2:E8
Driscoll, T., 59
Droste, S., 917
DuBose, T. D., Jr., 4:E8, 5:xlv, 1190
Dunea, G., 1033

Eiam-Ong, S., 1180
Eisele, G., 111
Eisen, T. D., 36
Eknoyan, G., 142, 1004
Elisaf, M. S., 1100
El-Shahawy, M. A., 118
Emerson, P. F., 344
Emili, S., 1107
Endo, K., 754
Endo, Y., 3:E6
Erlandson, R. A., 555
Escobar, F., 977
Espárrago, J. F., 892
Esteban, J., 3:E5

Faich, G., 464
Falcón, T. G., 21
Fasano, M. E., 1071
Fassi, A., 267
Feehally, J., 1049
Feinfeld, D. A., 5:E3
Feldman, C., 1131
Fenves, A. Z., 369
Ferguson, R. M., 150, 389
Fernández, M. C., 786
Fernández Rivera, C., 21
Ferrer, M. C., 43
Finazzi, S., 492
Fink, J. C., 97
Finkel, K. W., 1:E2, 2:E2, 3:E2, 4:E2, 4:E8, 5:E2, 6:E2
Finkelstein, F. O., 36
Flanigan, M. J., 6:E3
Floege, J., 434
Flombaum, C. D., 555
Fogo, A. B., 1:E1, 225, 404, 2:E1, 3:E1, 4:E1, 998, 5:E1, 6:E1
Fontán, M. P., 21
Fop, F., 1071
Fortes, J. R., 3:E5
Foulks, C. J., 186
Fracasso, A., 105
Frankenfield, D. L., 584, 1187, 6:E3
Franssen, C. F. M., 6:E5
Frederick, P., 6:E3
Freedman, B. I., 294
Frei, U., 2:E10
Fried, L., 927, 1136
Friedman, E. A., 728
Frye, R. F., 111
Fujii, T., 29, 261
Fujisaki, T., 1091
Fukagawa, M., 1091
Fung, K. S., 535
Furuichi, K., 1040
Furuya, R., 361
Futrakul, N., 886, 5:E5
Futrakul, P., 886, 5:E5
Futrakul, S., 886, 5:E5

Gadallah, M. F., 118
Gadea, I., 3:E5
Gafter, U., 82
Gallego, E., 458
Gallegos, G., 3:E5
Gambaro, G., 105, 807
Ganz, G., 4:E5
Garber, R. L., 970
Garber, S. L., 1033
García, J., 458
Gardner, J., 97
Garrett, B., 694
Geiger, X., 998
Gelein, R., 541
Ghantous, V. E., 36
Giraldo, A., 1164
Gitomer, J. J., 1:E2, 2:E2, 3:E2, 4:E2, 4:E8, 5:E2, 6:E2
Glover, J. J., 688
Glynne, P., 133
Goffin, E., 383
Gokal, R., 617
Goldfarb, D. S., 398
Goldstein, S. L., 518
Golper, T. A., 507, 617
González, J., 1018
Gonzalez-Pacheco, F. R., 1018
Goral, S., 998
Gotch, F., 1131
Grabe, D. W., 111
Grabensee, B., 934
Grcevska, L., 652
Grewal, M., 607
Grimm, E. M., 3:E2, 5:E2, 6:E2
Gröne, H. J., 434
Gudat, F., 1153
Gulati, M. S., 2:E9
Gunasekaran, H., 2:E5
Gunasekaran, S., 2:E5
Gunnell, J., 63
Gupta, S., 498

Haag-Weber, M., 334, 722
Hachey, D. L., 59
Haedecke, C., 4:E3
Hakim, R. M., 1, 217
Halford, H., 966
Halin, N., 1168
Halloran, P. F., 150
Halperin, M. L., 1147
Hameleers, P., 1115
Hanslik, T., 498
Hara, M., 3:E6
Hara, S., 3:E6
Harm, F., 702
Harmon, W. E., 567
Harris, D., 998
Hasegawa, S., 1158
Hattori, M., 427
Hauser, A.-C., 702
Heering, P., 934
Held, P. J., 1
Helderman, J. H., 138, 389, 998
Helgerson, S. D., 584
Hendricks, S. K., 917

Henrich, W. L., 6:xlix
Herman, M., 82
Herrero, J. C., 52
Herzog, C. A., 1080
Hesse, U., 934
Hibi, I., 361
Hida, M., 1091
Hildebrand, T.-S., 2:E10
Hiller, R., 1:E4
Hines, S. C., 688
Hirato, J., 2:E7
Hiromura, K., 2:E7
Hirsh, J., 82
Hirshberg, B., 161
Hisada, Y., 1040
Hite, S. H., 374
Hogan, M. B., 6:E7
Holley, J. L., 688
Hollomby, D., 6:E6
Hong, C. D., 312
Hörl, W. H., 2:xlv, 334, 722
Hotta, N., 738
Hornberger, J., 829, 1131
Hou, S., 235
Howell, D. N., 970
Hricik, D. E., 829
Huang, J.-W., 4:E6
Huch, K. M., 899
Hulbert-Shearon, T. E., 507
Hull, A. R., 389
Hunley, T. E., 404
Hussain, A., 5:E3

Ichiryu, M. S., 866
Iesato, K., 1158
Ifudu, O., 728
Iizuka, T., 276
Imai, H., 123
Inenaga, T., 29, 261
Inoue, T., 287
Iofel, Y., 728
Ishida, A., 3:E6
Iskandar, S. S., 552
Ito, H., 276
Ito, K., 427
Ivanovich, P., 563

Jabs, K., 253
Jacob, L. P., 301
Jacquot, C., 840
Jadoul, M., 1011
Jamar, F., 383
Jarolim, P., 1190
Jehle, P. M., 304
Jevnikar, A., 6:E6
Johannsson, G., 709
Johnson, L. Z., 786
Johnson, R. J., 225
Johnston, J. R., 963, 927, 1136
Jones, M., 203
Jothy, S., 128
Juncos, L. A., 43
Juncos, L. I., 43
Jungthirapanich, J., 886, 5:E5

Kahan, B. D., 150
Kaitwatcharachai, C., 1147
Kakuta, T., 1091
Kambham, N., 954
Kanatsuka, A., 276
Kaneko, Y., 772
Kangawa, K., 772
Kant, K. S., 694
Kappel, J. E., 3:E4
Karabina, S.-A., 1100
Kashtan, C. E., 374
Kasinath, B. S., 786
Kato, T., 1040
Katori, H., 3:E6
Kaufman, J., 6:E8
Kawaguchi, H., 427
Kawamura, T., 738
Kaysen, G. A., 63
Keane, W. F., 1004
Keilani, T., 450
Keller, F., 304
Kerkhofs, A. M. M., 1115
Keshaviah, P. R., 344
Keuneke, C., 379
Khairullah, Q. T., 1164
Khalil, M., 1142
Khono, M., 427
Kim, C.-M., 73
Kim, S. B., 312
Kim, S. Y., 73
Kim, Y.-G., 225
Kim, Y.-S., 73
Kimura, G., 29, 261
King, A. J., 1168
Kingwatanakul, P., 886, 5:E5
Kirkpatrick, B. S., 389
Kitahara, T., 2:E7
Kitamura, Y., 3:E6
Kitzwögerer, M., 702
Kivlighn, S. D., 225
Klassen, J., 3:E4
Klein, J. B., 483
Kleiner, M. J., 954
Klinkmann, J., 563
Ko, C. W., 778
Kobayashi, K.-i., 1040
Kobayasi, M., 3:E6
Kohaut, E., 567
Kohlhepp, S. J., 790
Kok, D. J., 761
Komatsuda, A., 123
Kongsin, P., 886, 5:E5
Konomoto, T., 427
Koo, J. H., 778
Kooman, J. P., 1115
Kopple, J. D., 180
Korzets, A., 82
Krane, N. K., 872
Kubo, A., 772
Kumagai, H., 361
Kuramoto, N., 276
Kurioka, H., 772
Kuroda, S., 29, 261
Kurokawa, K., 1091
Kurooka, K., 772
Kusano, S., 754
Kusek, J., 142
Kushida, K., 287
Kuypers, D., 2:E3
Kwan, T.-h., 6:E4

Lacson, E., 498
Lai, K. B., 318
Lai, K. N., 318, 535
Laissue, J. A., 1153
Laluck, B. J., Jr., 1026
Lam, C. W. K., 318
Lam, C.-s., 6:E4
Lambert, M.-C., 934
Lameire, N. H., 4:lii, 934
Lane, P. H., 1058
Laohapaibul, A., 886, 5:E5
Lasseur, C., 5:E4
Law, M. C., 535
Lazarus, J. M., 211, 523
Le, T., 1198
Lee, M., 718
Lee, S. M., 404
Leggat, J. E., Jr., 601
Lemann, J., Jr., 223
Lens, X. M., 1:E3
Leung, C. B., 535
Leung, J. C. K., 318
Leunissen, K. M. L., 1115
Levin, A., 4:E5
Levine, D. Z., 980
Levy, M., 128
Lew, N. L., 523
Lew, S. Q., 2:E6
Leypoldt, J. K., 349
Li, C. S., 535
Li, P. K. T., 535, 1064
Light, J. A., 150
Light, P., 97
Lightstone, L., 133
Lilaj, T., 334, 722
Lindberg, J. S., 718, 941
Lindsay, R. M., 471
Loertscher, R., 128
Loo, A. V., 934
López, M. D., 1018
Lopez-Baena, J. A., 904
Lorenz, M., 722
Lowrie, E. G., 523, 584
Lui, S. F., 535
Lund, J., 541
Lundin, A. P., 221
Lynch, D., 694

McCann, L., 1131
McCauley, J., 963

McClaughlin, K., 6:E6
McClellan, W. M., 584, 1187
McCormick, M., 253
McCowen, K. C., 172
McDonald, J., 118
Macía, M., 458
McLeish, K. R., 483
Maes, B., 2:E3
Maezawa, A., 2:E7
Magil, A. B., 4:E5, 866
Mahnensmith, R. L., 920
Mailley, J., 1049
Maiolo, A. T., 492
Maiorca, R., 857
Makino, H., 276
Malasit, P., 1147
Malhotra, D., 301
Malik, G., 1142
Mango, G. W., 541
Mangold, T. A., 899
Manuel, A., 325
Manzati, E., 880
Mardaras, J., 1:E3
Markowitz, G. S., 441, 954
Maroni, B. J., 176
Marsen, T. A., 3:E3
Martell, N., 1018
Martinez, I., 786
Martínez, M. A., 52
Martínez-Maldonado, M., 410
Maru, L., 1131
Marwali, M. R., 4:E5
Marwick, T. H., 1080
Matas, A. J., 150
Mathur, R. S., 917
Matsuo, S., 738
Matsushita, Y., 3:E6
Matzke, G. R., 595
Mazzola, G., 857, 1071
Means, R. T., Jr., 140
Meier-Kriesche, H.-U., 4:E8
Méndez, M. L., 458
Meyer, M. M., 790
Meyrier, A. Y., 801, 840
Micheletti, F., 880
Milionis, H. J., 1100
Miller, E. R., 356
Miller, F., 2:E9
Minamino, N., 772
Mingkum, S., 1147
Minutolo, R., 851
Mir, R., 5:E3
Mirochnik, Y., 1033
Mitch, W. E., 176
Mitwalli, A., 1142
Miura, A. B., 123
Miyaji, K., 361
Moayyedi, P., 1049
Molony, D. A., 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
Molteni, A., 450
Monaco, A. P., 150
Mora, C., 458
Morales, E., 52
Moss, A. H., 688
Mouradian, J. A., 555
Movilli, E., 857
Muchant, D. G., 6:E7
Mueller, B. A., 87
Muirhead, N., 6:E6
Munar, M. Y., 790
Murotani, N., 1158

Nakamoto, Y., 123
Nakamura, S., 29, 261
Napathorn, S., 282
Naruse, T., 2:E7
Nast, C. C., 1198
Navarro, J. F., 458
Neff, M. S., 601
Newman, R. B., 917
Nibbe, L., 2:E10
Nicola, B., 857
Nimmannit, S., 1147
Nishikawa, T., 276
Nishikino, M., 361
Nishimura, M., 29, 261
Nishitani, Y., 772
Nissenson, A. R., 471, 1122
Nizze, H., 761
Nojima, Y., 2:E7
Nolph, K. D., 344
Nonaka, H., 772
Noordermeer, C., 761
Nord, E. P., 2:E9
Noris, M., 746
Novoa, D., 1:E3
Nozaki, O., 276
Nuovo, M., 5:E3

Odamaki, M., 361
O'Donovan, R., 872
Ogundipe, A., 498
Oh, Y. S., 73
Ohmura, A., 287
Ohno, Y., 738
Ohta, S., 1040
Ohtani, H., 123
Okada, K., 772
Omura, M., 276
Ono, Y., 772
Ori, Y., 82
Ortiz, A., 3:E5
Ossi, E., 105
Owen, W. F., Jr., 170, 584

Panzarino, V., 374
Park, C. W., 73
Park, J. S., 312
Patnaik, M., 734
Paueksakon, P., 404, 607
Paul, R. V., 1107
Pellegrin, J.-L., 5:E4
Peng, Y.-S., 4:E6
Penolazzi, L., 880
Perazella, M. A., 782, 920
Pereira, B. J. G., 349
Perico, N., 267
Pervez, A., 118
Peter, J. B., 734
Pheley, A. M., 1080
Phillips, C. L., 814
Piccoli, G., 1071
Pickett, J. L., 1122
Pintos, E., 1:E3
Piraino, B., 927, 1136
Pisani, A., 851
Piva, R., 880
Pizarro, J. L., 892
Polenakovik, M., 652
Polissar, N., 675
Pollok, M., 3:E3
Polo, J., 904
Polo, J. R., 904
Poon, E., 1064
Porcella, A., 492
Port, F. K., 1, 349, 507, 601
Portman, R. J., 667
Praditpornsilpa, K., 282
Praga, M., 52
Prasad, G. V. R., 963
Prati, E., 857
Pribasnig, A., 702
Provenzano, R., 1164
Prowant, B. F., 1187, 6:E3
Pylypchuk, G. B., 3:E4

Que, T.-l., 6:E4

Rabb, H., 2:E5
Rahman, M., 498
Rahman, S. N., 694
Raj, D. S. C., 325
Rao, V. K., 1080
Rémésy, C., 633
Remuzzi, A., 267
Remuzzi, G., 267, 746, 807
Rexing, C. J., 1107
Reyero, A., 3:E5
Reynolds, D., 880
Reynolds, S. D., 541
Rice, L., 59
Rich, S. S., 294
Rivero, M., 458
Roberts, J. M., 992
Rocco, M. V., 584, 1187, 6:E3
Rodríguez-Carmona, A., 21
Roh, B. H., 294
Rohr, M. S., 552
Romero, J. C., 43
Romero, R., 1:E3
Ronco, C., 3:1
Roscoe, J., 325
Rosenberg, F., 4:E5
Ross, J. L., 718
Rossi, N. F., 4:E5

Rovira, A., 1018
Rueda, J. A., 904
Ruilope, L. M., 1018
Russo, D., 851
Rutecki, G., 2:E8
Ryan, C., 198

Saba, S. R., 2:E5
Sabatini, S., 389
Sadallah, S., 1153
Sadler, R., 941
Saeki, N., 1158
Saimopoulos, K. C., 1100
Saito, A., 1091
Saito, Y., 276
Sakai, H., 1091
Sakai, N., 1040
Salama, A., 133
Sale, M., 294
Salem, M., 592
Sampaolessi, A. H., 43
Sanabia, J., 904
Sanchez-Guisande, D., 1:E3
Sanden, S., 4:E3
Sandrini, M., 857
Sangalli, F., 267
Sarkar, S., 1136
Sarnak, M. J., 1168
Sato, S., 2:E7
Savino, F. A., 851
Savoldi, S., 857
Schifferli, J.-A., 1153
Schindler, R., 2:E10
Schlöndorff, D., 379, 4:E3
Schlueter, W. A., 450
Schneider, B., 334
Schoenberg, M. H., 304
Schoenfeld, F., 694
Schröder, F. H., 761
Schweitzer, S. U., 1122
Scoble, J. E., 975
Scolari, F., 857
Scott, M. K., 87
Segawa, C., 1040
Seigle, R. L., 441
Seligman, P., 471
Sensirivatana, R., 886, 5:E5
Seshan, S. V., 441
Settle, S. M., 910
Shah, B. R., 947
Shapiro, J. I., 301
Shappell, S., 607
Shayakul, C., 1190
Sherman, A. H., 36
Sherrard, D., 941
Shields, M. W., 910
Shimada, T., 1158
Shimizu, S., 287
Shimuzu, M., 1040
Shin, Y. S., 73
Singh, H., 1:E4
Singh, S., 4:E5
Singkhwa, V., 886, 5:E5
Sitprija, V., 282, 1180
Slatopolsky, E., 694
Smith, A. M., 2:E6
Smith, M. C., 498
Soldevilla, M. J., 1018
Solez, K., 150
Somlo, S., 880
Sorof, J. M., 518, 667
Sorrells, D., 118
Sowinski, K. M., 87
Spath, P. J., 1153
Spiera, H., 4:E7
Spray, B. J., 294
Squifflet, J.-P., 1011
Staffeld, C., 718
Stampfer, M. J., 398
Stannard, D. C., 1, 349
Steere, E. L., 899
Stegeman, C. A., 6:E5
Stehman-Breen, C. O., 11, 941
Steinman, T. I., 798
Sterns, R. H., 161
Stokes, M. B., 658
Stracke, S., 304
Strandness, D. E., Jr., 675
Stratta, P., 1071
Stripp, B. R., 541
Strobos, J., 464, 471
Sturm, D., 304
Suga, S., 225
Sugawara, M., 2:E7
Suki, W. N., 59, 796
Sullivan, S. D., 829
Suzuki, H., 1091
Swan, S., 471
Swirsky, D., 133
Szeto, C. C., 318, 535
Szeto, M.-l., 6:E4

Tagami, T., 3:E6
Tai, C., 4:E5
Takeji, M., 29
Takemoto, F., 3:E6
Tan, B. J., 3:E4
Tarif, N., 1142
Taylor, L., 6:E3
Teitelbaum, I., 694
Thakur, S., 2:E4
Theberge, D. C., 1122
Thuwajit, P., 1147
Tobé, T. J. M., 6:E5
Todeschini, M., 746
Tokars, K. I., 356
Tong, K. L., 535
Tootell, F., 1131
Torres, J. R., 647
Torres, M., 1131
Tosukhowong, P., 1180
Tsai, T.-J., 4:E6
Tsang, W. K., 535
Tselepis, A., 1100
Tsuchida, H., 276
Tsushima, Y., 754
Tullis, M. J., 675
Tungsaga, K., 282
Tungsanga, K., 1180
Turner, M., 97
Turney, J. H., 1049

Ubara, Y., 3:E6
Ueki, K., 2:E7
Ullian, M. E., 1107
Umans, J. G., 992
Uribarri, J., 4:E7
Uzu, T., 29, 261

Valcourt, J. S., 728
Valdés, F., 21
Valenti, G., 492
Valzorio, B., 857
Van Biesen, W., 934
Van Buren, D., 998
Van Damme, B., 2:E3
Van der Kwast, T. H., 761
Van der Sande, F. M., 1115
Van der Vennet, M., 934
Vanholder, R., 934
Vanrenterghem, Y., 2:E3
Vanwalleghem, J., 2:E3
Van Ypersele de Strihou, C., 1011
Vara, J., 52
Varelas, P. N., 966
Vasuvattakul, S., 1147
Vazini, N. D., 821
Vázquez, R., 904
Veenstra, D. L., 829
Velosa, J. A., 734
Viola, B. F., 857
Vogt, B. A., 374
Von Wussow, P., 434
Vychytil, A., 334, 722

Wada, T., 1040
Waer, M., 2:E3
Wakai, K., 738
Wakashin, M., 1158
Wakui, H., 123
Walker, A., 941
Wall, B. M., 899
Wankrairot, P., 282
Warady, B. A., 567
Ward, R. A., 483
Watana, D., 886, 5:E5
Watkins, S., 567
Weigel, K., 498
Weinstein, T., 82
Weisinger, J. R., 1:xliii
Wese, F.-X., 1011
White, C. W., 1080
Whitley, C. E., 59
Whyte, R. L., 2:E6
Widmaier, U., 304
Wiebecke, B., 4:E3

Wiesholzer, M., 702
Wilairat, P., 1147
Wilson, N. W., 6:E7
Winn, M. P., 970
Winston, J., 4:E7
Wisse, B., 2:E4
Wolf, G. L., 804
Wolfe, R. A., 1, 507
Wolfson, M., 203
Wong, K. M., 535
Wong, T. Y. H., 1064
Work, J., 118, 325
Wu, M.-S., 4:E6

Xenocostas, A., 128

Yagui, K., 276
Yamada, A., 3:E6
Yamamoto, S., 1158
Yamazaki, K., 287
Yang, W. S., 312
Yano, S., 2:E7
Yasuda, T., 123
Yee, Y.-k., 6:E4
Yenchitsomanus, P.-t., 1147
Yenrudi, S., 282, 886, 5:E5
Yeun, J. Y., 63
Yeung, C. K., 4:E5
Yiu, V., 253
Yokoo, H., 563
Yokota, M., 3:E6
Yokoyama, H., 1040
Yokoyama, K., 3:E6
Yoneyama, T., 361
Yoshida, H., 1158
Yoshihara, K., 3:E6
Yoshioka, T., 427
Younes, H., 633
Young, E. W., 507
Yu, H., 294
Yung, C.-y., 6:E4

Zeig, S., 694
Zevin, D., 82
Zhang, S. M. H., 523
Zhu, X., 523
Zibari, G., 118
Zierler, R. E., 675
Zijlstra, J. G., 6:E5
Zoja, C., 746
Zurakowski, D., 253

SUBJECT INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.
Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.
Page references to Supplement 1 (April 1999) are preceded by S1:.

AAs, *see* Amino acids
Ab(s), *see* Antibodies
ABPM, *see* Ambulatory blood pressure monitoring on chronic HD
Access, vascular, *see* Catheters, CAPD; Vascular access, HD
ACE, *see* Angiotensin-converting enzyme; Angiotensin-converting enzyme gene polymorphism; Angiotensin-converting enzyme inhibitor(s)
Acidosis, *see* Distal renal tubular acidosis; Metabolic acidosis
ACP, *see* Advance care planning in dialysis
Acquired immunodeficiency syndrome, *see* AIDS
Acromegaly-complicated nephrotic syndrome (NS), minimal change, with FSGS, effects of pituitary microsurgery on, 1158-1163
Acute graft failure, incidence of, with prior HD and/or CAPD, 934-940
Acute hyperkalemia in CRF, IV EACA-associated, 782-785
Acute liver failure (ALF) with ARF, severe hypocalcemia during CVVHD with regional citrate anticoagulation for, 4:E8
Acute necrotizing glomerulonephritis (GN), Hantavirus-positive serology with, 736
Acute-phase response predicting resistance to rHuEPO, 63-72
Acute rejection
  chronic rejection linked to, 152-153
  Hantavirus-positive serology with, 736
Acute renal diseases (ARDs)
  Hantavirus-specific IgG, IgA, IgM in congenital renal diseases versus CRDs and, 734-737
  see also specific conditions
Acute renal failure (ARF)
  ALF with, severe hypocalcemia during CVVHD with regional citrate anticoagulation for, 4:E8
  with disseminated CCE, 840-850, 975-976
  due to MM and ACE inhibitors, 2:E5
  ESWL and, 128-132
  post-RTx nonoliguric, 166-169
  serotonin and RBF regulation in, 4:lii-liv
Acute tubulointerstitial nephritis (TIN), cimetidine-induced ANCA-associated, 2:E7
AD(s) (advance directives), 981-983
Adaptation
  metabolic, to dietary protein restriction, 177-178
  psychological, by pediatric ESRD patients on CAPD and/or HD, 577
Adenosine triphosphatase, *see* ATPase
Adequacy of CAPD, CCPD, and/or HD for ESRD
  center and random effects on, 97-104
  Core Indicators Project Report (1997) on, 6:E3
  in Europe, 3:l-lii
  HEMO Study on, 142-149
  IDPN effects on, 1131-1135
  as outcome measure in MCOs, S1:10
  for pediatric ESRD, 569-571
  and relationship between URR, demographic characteristics, and BW, 584-591
  tolerance of large exchange volumes by CAPD patients, 1136-1141
  see also Adequacy of CAPD for ESRD, mortality and morbidity in redefinition of; Kt/V, and CAPD and/or HD for ESRD; Kt/V_{urea}, and adequacy of CAPD

Adequacy of CAPD for ESRD, mortality and morbidity in redefinition of, 617-632
importance of solute clearance in assessing, 618-621
nutrition and, 625-627
risk factors for CV disease and, 621-625
specific recommendations on, 628
ADH, *see* Antidiuretic hormone
Adipsic hypernatremia with AIDS and CMV encephalitis, ADH in, 379-382
ADPKD, *see* Autosomal dominant polycystic kidney disease
β (beta)-Adrenergic blockers for pregnant ESRD patients, 242
Adrenomedullin (AM), urinary, in cystitis, 772-777
Adult-onset primary hyperoxaluria (PH), steroid-responsive pleuropericarditis and livedo reticularis in, 4:E5
Advance care planning (ACP) in dialysis, 980-991
and ADs, 981-983
case presentation of, 980-981
conclusions on, 986-987
defined, 983
to elicit patients' preferences for withdrawal from chronic HD, 688-693
framework for treatment decision making in, 984-986
new model of, 984
questions and answers on, 983-989
traditional concept of, 983-984
Advance directives (ADs), 981-983
Advanced renal failure, diabetic nephropathy with, PTF effects on proteinuria and serum TNF-α in, 458-463
AE1 gene mutation in dRTA
autosomal dominant dRTA, 1190-1197
with SAO, 1147-1152
African Americans, *see* Race and ethnicity
Age
and ARAS, 677
of CG patients, 655, 660
of CHF patients, 44
of CHN patients, 1013
of diabetic nephropathy patients, 277, 459, 1066, 1067
of ESRD patients, *see* Age of ESRD patients on CAPD and/or HD; Age of hypertensive ESRD patients
of FSGS patients, 54, 55, 655
fvv, α/V and, 757-758
of Gitelman's syndrome patients, 779
of HCDD patients, 958
of HCV infection patients, 1041
of HSP patients, 429, 435
of hyporeninemic patients, 949
of IgAN patients, 435, 739, 861, 1073
of β_2-M amyloidosis patients, 565
of MGN patients, 1027-1029
of primary aldosteronism patients, 262, 263
of SCI patients, proteinuria and, 900, 901
of SLE patients with HIV infection, 443, 447
see also Age of RTx recipients; Aging *and entries beginning with term*: Pediatric
Age of ESRD patients on CAPD and/or HD
adequacy of HD and, 99, 101
apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1101
with CAD, 1083
or CCPD, mortality and, 524, 525, 530
on chronic HD, *see* Age of ESRD patients on chronic HD
with double-bag and Y-set disconnect systems and, 536
folate measurements and, 494
gestational age and HD effects on serum progesterone, 918
hospitalization and, 928, 929
with HPT, 305, 696
with HTN, *see* Age of hypertensive ESRD patients
on IDPN, 1133
and increasing serum albumin effects on plasma D-dimer, von Willebrand factor, and platelet aggregation, 313
and indications for CAPD catheter tunnel ultrasound, 723
with intradialytic hypotension, 992, 1109
and IV iron dextran and Ferrlecit effects, 468
with peritonitis, intermittent IP ceftazidime therapy and, 115
persistent SLE and, 873
and predialysis BP, 509
and preterminal pulmonary thromboembolism, 705, 706
race and, *see* Age of ESRD patients on CAPD and/or HD, race and
with RAS, 38
relationship of dialysis membranes to mortality and, 5
and relationship between URR, BW and, 586, 587
and resistance to rHuEPO, 65-67
with ROS, 288, 289
Tenckhoff catheter placement and, 119
and tolerance of large exchange volumes, 1137
Age of ESRD patients on CAPD and/or HD, race and
BMD, bone loss and, 942-944
and CAPD utilization, 326, 329
Age of ESRD patients on chronic HD
home BP monitoring and, 683
and preferences for withdrawal from dialysis, 689
serum leptin association with weight loss and, 365
Age of hypertensive ESRD patients
aortic dissection in young patients with CRI, 374-378
HTN control and, 500, 501, 503
with nondipper type essential HTN, 30
and post-RTx HTN, 24, 25
Age of RTx recipients
HD and/or CAPD before, and graft failure, 936
and post-RTx HTN, 24, 25
vitamin K deficiency, hemorrhage and, 964
Aging
and hyperuricemia, 229
see also Elderly ESRD patients
AIDS (acquired immunodeficiency syndrome)
adipsic hypernatremia with CMV encephalitis and, 379-382
see also HIV infection; HIVAN
Al, *see* Aluminum, rHuEPO and
Alanine aminotransferase (ALT) in ESRD patients on CCPD, mortality and, 525
Albumin
in MGN and mesangial GN, IFN-α effects on, 1143
see also Albumin in ESRD patients on CAPD and/or HD; Albuminuria; Serum albumin
Albumin in ESRD patients on CAPD and/or HD
or CCPD, mortality and, 525
clearance of, with bleach-reprocessed high-flux dialyzers, 92

hypoalbuminemia and massive proteinuria in FSGS secondary to hyperfiltration, 52-58
IDPN effects on, 199
intradialytic hypotension and, 923
or IPD, APD, and TPD, 334-343
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
and relationship between URR, demographic characteristics, and BW, 589
and resistance to rHuEPO, 63-72
see also Prealbumin in ESRD patients on CAPD and/or HD; Serum albumin in ESRD patients on CAPD and/or HD
Albuminuria
low-dose ramipril effects on, 453
in NIDDM nephropathy, 1066
quantification of, 1006
testing for, 1005-1006
see also Macroalbuminuria; Microalbuminuria; Proteinuria
Alcohol intake
and hypertensive ESRD, 500, 501
and IgAN, 741
Aldosterone, *see* Plasma aldosterone
Aldosteronism, primary, CV events with, 261-266
ALF (acute liver failure) with ARF, severe hypocalcemia during CVVHD with regional citrate anticoagulation for, 4:E8
Alfacalcidol [1α(OH)D_3], pulse, for secondary HPT in ESRD patients on CAPD treated with 1.0 and 1.25 mmol/L Ca dialysate, Ca balance in, 82-86
Alkali therapy of hyperkalemic metabolic acidosis, 5:xlvii
Alkaline phosphatase (ALP) in ESRD patients on HD
or CCPD, ESRD, mortality and, 525
with HPT, 75, 699
and metabolic acidosis in diabetic and nondiabetic ESRD patients, 894
serum, with ROS, 288-291
Allergic/anaphylactic reactions to IV iron dextran and Ferrlecit, compared, 467-469
ALP, *see* Alkaline phosphatase in ESRD patients on HD
Alpha (α) methyldopa for pregnant ESRD patients, 242
Alport's syndrome, as primary disease, 119, 668
ALT (alanine aminotransferase) in ESRD patients on CCPD, mortality and, 525
Aluminum (Al), rHuEPO and
and resistance to rHuEPO, 65-68
rHuEPO effects on aluminum, 1125
AM (adrenomedullin), urinary, in cystitis, 772-777
Ambulatory blood pressure monitoring (ABPM) on chronic HD
IDWG and, in pediatric patients, 667-674
interdialytic, 682-687
Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis for ESRD
Amino acids (AAs)
absorption of, with IDPN, 203-204
renal vasodilation in CHF due to, enalapril for, 43-51
see also specific amino acids
ϵ (epsilon)-Aminocaproic acid (EACA), acute hyperkalemia associated with IV, in CRF, 782-785
Ammonia (NH_3), enterohepatic cycling of, relationship between fermentable carbohydrates and, 637-639
Ammonium, *see* NH_4
Amyloidosis
β_2M, cervical spondyloarthropathy with, in ESRD patients on HD, mortality due to, 563-566
Hantavirus-positive serology with, 736
and SCI, 899-903
Anabolic effects of GH therapy for elderly chronic HD patients, 709-717
Analgesic nephropathy, as primary disease, 305
Anaphylactic/allergic reactions to IV iron dextran and Ferrlecit, compared, 467-469
ANCAs, *see* Antineutrophil cytoplasmic antibodies
Anemia
in IDDM with hyporeninemia, 947-953
see also Anemia of ESRD
Anemia of ESRD
in pregnancy, 245-246
safety of IV Ferrlecit and iron dextran for, compared, 464-482, 595-597
see also Recombinant human erythropoietin for anemic ESRD patients
Aneurysms, renal and extrarenal arterial, associated with Ask-Upmark kidney, 4:E4
Angiography
CAD screening with, in ESRD patients, 1083
and disseminated CCE, 840-850, 975-976
Gd-enhanced magnetic resonance, RAS in CRF evaluated with, 36-42
Angioplasty to determine causes of nonfunctioning AVF, 910-916
Angiotensin II (ANGII), IV calcitriol effects on, in ESRD patients on HD with secondary HPT, 77
Angiotensin-converting enzyme (ACE)
serum, low-dose ramipril effects on, 453
see also Angiotensin converting enzyme gene polymorphism
Angiotensin-converting enzyme (ACE) gene, I/D polymorphism of
effects of, on IgAN progression, 1071-1079
in NIDDM with insulin resistance, 276-281
Angiotensin converting enzyme (ACE) gene polymorphism
of DD/II gene in Chinese NIDDM population, renal function and, 1064-1070
see also Angiotensin-converting enzyme gene, I/D polymorphism of
Angiotensin-converting enzyme (ACE) inhibitor(s)
and ARAS, 675-681
ARF due to MM and precipitated by, 2:E5
enalapril as, for renal vasodilation due to AA infusion in CHF, 43-51
lisinopril as, effects of molsidomine and, on remnant kidney, 746-753
for pregnant ESRD patients, 241-242
for proteinuria, *see* Angiotensin-converting enzyme inhibitor(s) for proteinuria
Angiotensin-converting enzyme (ACE) inhibitor(s) for proteinuria
and hyperkalemia, effects of low-dose ramipril on, 450-457

in normotensive IgAN patients, effects of ACE inhibitors with losartan on, 851-856
Angiotensinogen (Atg) M235T gene, polymorphism of, and renal function in Chinese NIDDM population, 1064-1079
Anion gap in for ESRD
CCPD, mortality and, 525
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
Anionic exchange
in environmental dRTA, 1180-1186
in SAO, 1147-1152
Anorexia in dialyzed ESRD patients, 178
ANPs, *see* Atrial natriuretic peptides in ESRD patients on HD
Antibiotics
for cystitis, effects of, on AM, 774-775
see also specific antibiotics
Antibodies (Abs)
anti-GBM, in pediatric pulmonary hemorrhage with skin lesions and hematuria, 404-409
antineutrophil cytoplasmic, *see* Antineutrophil cytoplasmic antibodies
polyclonal, in pregnancy, 240
systemic, response of, to mucosal *H pylori* infection in IgAN, 1049-1057
Anticoagulation
anticoagulants in disseminated CCE, 840-850, 975-976
CVVHD with regional citrate, severe hypocalcemia during, 4:E8
for dialyzed ESRD pregnant patients, 247
Antidiuretic hormone (ADH; vasopressin)
in adipsic hypernatremia due to CMV encephalitis and AIDS, 379-382
IV calcitriol effects on, in ESRD patients on HD with secondary HPT, 76, 77
and SIADH, 161-165
Antigen(s)
major histocompatibility class II, in CaOx nephrolithiasis, 761-771
Anti-glomerular basement membrane (GBM) antibodies (Abs) in pediatric pulmonary hemorrhage, skin lesions, and hematuria, 404-409
Anti-glomerular basement membrane (GBM) disease
IgA, with bronchial carcinoma and monoclonal gammopathy, 2:E3
as primary disease, 922
Anti-glomerular basement membrane glomerulonephritis (anti-GBM GN) following ESWL, 128-132
Antihypertensive medications, *see specific antihypertensive drugs*
Antineutrophil cytoplasmic antibodies (ANCAs)
ANCA-associated acute TIN induced by cimetidine, 2:E7
MPO-ANCA-positive CGN, PSS and, 4:E3
in pediatric pulmonary hemorrhage with skin lesions and hematuria, 404-409
Aortic dissection in young hypertensive patients with CRI, 374-378
APD, *see* Automated peritoneal dialysis for ESRD
Apolipoprotein(a) [apo(a)] phenotypes, Lp(a) concentrations and, in CRF patients, 1100-1106
Aquaporin-1 (AQP1) in long-term CCPD patients with impaired transcellular water transport, 383-388
ARAS (atherosclerotic renal artery stenosis), and ACE inhibitors for HTN, 675-681
ARDs, *see* Acute renal diseases
ARF, *see* Acute renal failure
L-Arginine inducing microalbuminuria in healthy individuals, 1018-1025
Arginine vasopressin, rHuEPO effects on, HTN and, 826
Aristocholic acid-containing Chinese herbs, urothelial lesions due to, 1011-1017, 1171-1173
Arterial aneurysms, renal and extrarenal, associated with Ask-Upmark kidney, 4:E4
Arteriovenous fistula (AVF), 904-916
brachiocephalic jump, as alternative to elbow crease fistula, 904-909, 977-979
salvage of nonfunctioning, 910-916, 977-979
Ask-Upmark kidney, renal and extrarenal arterial aneurysms associated with, 4:E4
Atg (angiotensinogen) M235T gene, polymorphism of, and renal function in Chinese NIDDM population, 1064-1079
Atheroembolism, treatment improving survival with, 840-850, 975-976
Atherosclerotic renal artery stenosis (ARAS), and ACE inhibitors for HTN, 675-681
Atlas of renal pathology, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
ATPase (adenosine triphosphatase)
in environmental dRTA, 1180-1186
H^+-, in SAO, 1147-1152
Atrial natriuretic peptides (ANPs) in ESRD patients on HD
rHuEPO effects on, HTN and, 826
with secondary HPT, IV calcitriol effects on, 76, 77
Atypia, and urothelial lesions in CHN, 1011-1017, 1171-1173
Autoimmune thyroiditis, MGN and, 369-373
Automated peritoneal dialysis (APD) for ESRD
for home-treated patients, 334-343
IDPN for pediatric patients on APD, 205-207
Autosomal dominant distal renal tubular acidosis (dRTA), *AE1* gene mutation in, 1190-1197
Autosomal dominant polycystic kidney disease (ADPKD)
PKD2 gene mutations in, 880-885
as primary disease, 99, 101, 729, 730
Autotransplantation, total PTX without, for HPT with ESRD, clinical course after, 304-311
Avascular necrosis of hip following RTx, incidence and long-term cost of steroid-related, 829-839
Average bioequivalence, defined, 390
AVF, *see* Arteriovenous fistula
Azathioprine in pregnancy, 239
Azotemia, priming of neutrophil oxidative burst dependent on, RTx correcting, 483-491

Bacteremia, *C canimorsus*. after dog bite, HUS due to, 6:E5
Band 3 protein, *see*: *AE1* gene mutation in dRTA
BEA (bromoethylamine)-induced papillary necrosis, evolution of, to FSGS and nephrotic-range proteinuria, 1033-1039
Bence-Jones proteins, and refractory graft dysfunction, 998-1003
Benefit language, coverage decisions and, 108

Berger's disease, *see* IgA nephropathy
Beta (β)-adrenergic blockers for pregnant ESRD patients, 242
Beta$_2$-microglobulin, *see* β_2-Microglobulin; β_2-Microglobulin amyloids
Beverages
  diet and, in prevention of nephrolithiasis, 398-403
  see also Alcohol intake
BF (blood flow), renal, serotonin and regulation of, in ARF, 4:lii-liv
Bicarbonate, *see* HCO_3
Bilateral emphysematous pyelonephritis due to *Candida* infection, 2:E10
Bilateral ophthalmoplegia and exophthalmos, and CVC placement for HD, 966-969
Bilirubin in ESRD patients on CCPD, mortality and, 525
Bioavailability, defined, 390
Bioequivalence
  average and individual, defined, 390
  defined, 390
  issues of, 392
  limitations of current testing of, 392-394
Biopsy, *see* Renal biopsy
Birthweight, relationship between childhood BP and, 253-260
Bisexual male, HIV-infected, nephrotic range proteinuria and hematuria in, 607-612
Black Americans, *see* Race and ethnicity
Blastokinin (Clara cell secretory protein; uteroglobin) deficiency, lack of Fn accumulation and normal renal function in, 541-551, 598-600
Bleach-reprocessed high-flux hemodialyzers, solute and water permeability changes with, 87-96
Blood flow (BF), renal, serotonin and regulation of, in ARF, 4:lii-liv
Blood pressure (BP)
  in CHF, effects of AA infusion on, 46
  in CRF, delayed referral and, 729, 730; *see also* Blood pressure of ESRD patients on CAPD and/or HD
  effects of ACE inhibitors with losartan on proteinuria in normotensive IgAN, 851-856
  with FSGS, 54
  in hyporeninemia, 949
  in IgAN, 1073
  lisinopril and molsidomine effects on, in remnant kidney, 748
  low-dose ramipril effects on, 452
  pediatric, relationship between birthweight and, 253-260
  see also Blood pressure in diabetic nephropathy; Hypertension; Hypotension
Blood pressure (BP) in diabetic nephropathy
  with advanced renal failure, 459
  in NIDDM nephropathy, 277, 1066
Blood pressure (BP) of ESRD patients on CAPD and/or HD and CAD, 1084
  chronic HD, home BP monitoring of, 682-687
  IV iron dextran and Ferrlecit effects on, 468
  predialysis, in diabetic ESRD, mortality and, 507-517, 592-594
  with secondary HPT, IV calcitriol effects on, 75
  see also Hypertensive end-stage renal disease; Interdialytic weight gain by ESRD patients, BP and
Blood urea nitrogen, *see* BUN in ESRD
BMD, *see* Bone mineral density
BMI, *see* Body mass and body mass index
Body mass index (BMI)
  of NIDDM nephropathy patients, 277, 1066, 1067
  of nondipper type essential HTN patients, 30
  of primary aldosteronism patients, 262, 263
  of ROS patients, 288, 289
  see also Body mass index of ESRD patients on CAPD and/or HD
Body mass index (BMI) of ESRD patients on CAPD and/or HD
  apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1101
  see also Body mass and body mass index of ESRD patients on CAPD and/or HD, mortality and
Body mass index (BMI) of ESRD patients on CAPD and/or HD, mortality and
  GH therapy effects on, in elderly chronic HD patients, 711
  predialysis BP and, 509
  relationship of dialysis membranes to mortality, 5
Body weight (BW)
  at birth, relationship between BP and, in childhood, 253-260
  of CRF patients, delayed referral and, 729, 730; *see also* Body weight of ESRD patients on CAPD and/or HD
  furosemide effects on, 1060
  of Gitelman's syndrome patients, 779
  of MGN and mesangial GN patients, IFN-α effects on, 1143
  of normotensive IgAN patients, effects of ACE inhibitors with losartan on, 852
  of RTx recipients, graft failure and, 936
  see also Obesity
Body weight (BW) of ESRD patients on CAPD and/or HD
  on chronic HD, and weight loss associated with serum leptin, 361-368
  of hypertensive ESRD patients, 500, 501, 503
  race, CAPD utilization and, 326, 329
  relationship between URR, demographic characteristics and, 584-591
  with secondary HPT, IV calcitriol effects on, 75
  Tenckhoff catheter placement and, 119
  see also Interdialytic weight gain by ESRD patients, BP and
Bone disease, renal, *see* Renal bone disease
Bone loss
  in hypercalciuria, 1:xlvi-xlviii
  racial differences in BMD and, in ESRD patients on HD, 941-946
Bone mineral density (BMD)
  bone loss and, in ESRD patients on HD, racial differences in, 941-946
  in hypercalciuria, 1:xlvi
  in ROS, 287-293
Bone resorption, drugs inhibiting, 1:xlvii-xlviii
BP, *see* Blood pressure
Brachiocephalic jump arteriovenous graft fistula (AVF), as alternative to elbow crease fistula, 904-909, 977-979
Brain function, effects of Hct normalization with rHuEPO on, in HD patients, 1122-1130, 1177-1179

Bromoethylamine (BEA)-induced papillary necrosis, evolution of, to FSGS and nephrotic-range proteinuria, 1033-1039
Bronchial carcinoma, IgA anti-GBM disease with monoclonal gammopathy and, 2:E3
BUN (blood urea nitrogen)
in SAO, 1149
see also BUN in ESRD
BUN (blood urea nitrogen) in ESRD
adequacy of HD and, 99
delayed referral and, 729, 730
IDPN effects on, 199
and preterminal pulmonary thromboembolism, 705, 706
rHuEPO effects on, 1125
in RTx recipients, vitamin K deficiency, hemorrhage and, 964
BW, *see* Body weight

C (complement), serum, in SLE with HIV infection, 443, 447
C albicans (*Candida albicans*)
bilateral emphysematous pyelonephritis due to, 2:E10
renal artery rupture secondary to graft contamination by, 1:E3
C canimorsus (*Capnocytophaga canimorsus*) bacteremia after dog bite, HUS due to, 6:E5
C1q (complement 1q) nephropathy, 5:E2
C3 (complement 3) in HCDD, 958
C4 (complement 4) in HCDD, 958
C4b/C3b inactivator (factor I) deficiency, GN with, 1153-1157
Ca (calcium)
urinary excretion of, in Gitelman's syndrome, GH therapy effects on, 779
see also Ca acetate; Ca channel blockers; Ca in ESRD patients on CAPD and/or HD; Calcium oxalate nephrolithiasis; Hypercalciuria; Hypocalcemia; Serum Ca
Ca (calcium) acetate, sevelamer hydrochloride and, for HPT with hyperphosphatemia and hypercholesterolemia in ESRD patients on HD, compared, 694-701
Ca (calcium) channel blockers
dose-response of CsA to, 301-303
effects of, on CsA-induced changes in GFR, 267-275
for pregnant ESRD patients, 242-243
Ca (calcium) in ESRD patients on CAPD and/or HD
or CCPD, mortality and, 525
cytosolic, PMNL function impaired by increased, 2:xlv-xlvi
intracellular, rHuEPO effects on, 825
intradialytic hypotension and, 923
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
pregnant dialyzed patients' needs in, 247
with secondary HPT, 75, 82-86
see also Serum Ca in ESRD patients on CAPD and/or HD
CAD, *see* Coronary artery disease
Calcineurin (CN), implications of inhibition of, for chronic rejection, 155
Calcitriol [1,25-dihydroxyvitamin D_3; 1,25-$(OH_2)D_3$], IV, effects of, on myocardial hypertrophy in ESRD patients on HD with secondary HPT, 73-81
Calcium, *see* Ca
Calcium oxalate (CaOx) nephrolithiasis, effects of, on cellular composition of interstitium, 761-771
Calculi, *see* Nephrolithiasis
Candida albicans, *see*: *C albicans*
CaOx (calcium oxalate) nephrolithiasis, effects of, on cellular composition of interstitium, 761-771
CAPD, *see* Continuous ambulatory peritoneal dialysis for ESRD
Capillary pressure, glomerular, effects of Ca channel blockers on CsA-induced changes in, 267-275
Capnocytophaga canimorsus (*C canimorsus*) bacteremia after dog bite, HUS due to, 6:E5
Carbohydrates, *see* Fermentable carbohydrates with low-protein diet for CRF
Carbon dioxide, *see* CO_2
Carcinoma, *see specific carcinomas*
Cardiac output, AA infusion on, in CHF, 46
Cardiovascular (CV) disease with ESRD
effects of hyperuricemia in, 225-234
risk factors for, *see* Risk factor(s) for CV disease in ESRD
see also Cardiovascular disease in ESRD patients on HD; Coronary artery disease in ESRD
Cardiovascular (CV) disease in ESRD patients on HD
hemodynamic instability and, 6:xlix-lii
hypertensive ESRD, mortality and, 507-517, 592-594
Cardiovascular (CV) renal disease, proteinuria in, 1006-1007
Cardiovascular (CV) system
effects of primary aldosteronism on, 261-266
see also Heart *entries beginning with terms*: Cardiovascular, Coronary, Renovascular *and element*: Vascul-
Cataracts in RTx recipients, incidence and long-term cost of steroid-related, 829-839
Catecholamines
rHuEPO effects on, HTN and, 823
see also Epinephrine; Norepinephrine
Catheters, *see* Catheters, CAPD; Catheters, HD
Catheters, CAPD
indications for tunnel ultrasound of, 722-727
Tenckhoff, surgical versus Y-TEC peritoneoscopic placement of, 118-122
see also Catheters, infected CAPD
Catheters, HD
double-lumen, access recirculation secondary to free flow between lumens of, 1168-1170
see also Central venous catheters, HD
Catheters, infected CAPD
catheter tunnel ultrasound for, 722-727
with double-bag and/or Y-set disconnect systems, compared, 535-540
with *Penicillium sp:*, 3:E5
Cation exchange resin in hyperkalemic metabolic acidosis, 5:xlvii-xlviii
CCE (cholesterol crystal embolism), disseminated, treatment improving survival with, 840-850, 975-976
CCPD, *see* Continuous cycling peritoneal dialysis for ESRD
CCSP (Clara cell secretory protein; uteroglobin; blastokinin) deficiency, lack of Fn accumulation and normal renal function in, 541-551, 598-600
Ceftazidime, intermittent IP, for peritonitis on CAPD, pharmacokinetics of, 111-117

Cellular composition of interstitium, CaOx nephrolithiasis effects on, 761-771
Cellular immunity in dialyzed patients
effects of low- and high-molecular-weight uremic toxins on, 2:xlvi-xlvii
PEM impairing, 2:xlv
Cellulose dialysis membranes, relationship of, to cause-specific mortality, 1-10
Center effects on adequacy of HD, 97-104
Central venous catheters (CVCs), HD
bilateral ophthalmoplegia and exophthalmos and placement of, 966-969
temporary HD, 718-721
Cervical spondyloarthropathy with systemic β_2M amyloid deposits in ESRD patients on HD, mortality due to, 563-566
CG, *see* Collapsing glomerulopathy
CGN, *see* Crescentic glomerulonephritis
CHD (coronary heart disease), disseminated CCE and, 847
CHF (congestive heart failure), renal vasodilation due to AA infusion in, enalapril for, 43-51
Child psychologist/psychiatrist, role of, with pediatric dialysis patients, 578-579
Children, *see entries beginning with term*: Pediatric
Chinese-herb nephropathy, *see* Interstitial fibrosis, Chinese herb-induced
Chinese population with NIDDM, polymorphism of ACE DD/II and Atg M235T genes, renal function and, 1064-1079
Chloramphenicol, serum and effluent, to aid in treatment of VRE peritonitis, 3:E4
Chloride, *see* Cl
CHN, *see* Interstitial fibrosis, Chinese herb-induced
Cholesterol
in MGN and mesangial GN, IFN-α effects on, 1143
in NIDDM nephropathy, 1066, 1067
see also Cholesterol crystal embolism; High-density lipoprotein-cholesterol; Hypercholesterolemia; Low-density lipoprotein-cholesterol in ESRD patients on CAPD and/or HD; Serum cholesterol; Total cholesterol
Cholesterol crystal embolism (CCE), disseminated, treatment improving survival with, 840-850, 975-976
Chronic glomerulonephritis (GN), as primary disease, 729, 730, 913
Chronic hemodialysis (HD) for ESRD, 349-368
effects of middle molecule removal and hemodialyzers on patient survival with, 349-355
in elderly patients, effects of GH therapy on, 709-717
HBV vaccine for patients on, 356-360
home BP monitoring on, 682-687
prognosis of parathyroid function after color Doppler flow-guided PEIT in patients on, 1091-1099
serum leptin associated with weight loss on, 361-368
see also Ambulatory blood pressure monitoring on chronic HD
Chronic hepatitis C virus (HCV) infection, exacerbation of GN and proteinuria following IFN therapy of, 1040-1048, 1174-1176
Chronic interstitial nephritis (IN), Hantavirus-positive serology with, 736
Chronic lymphocytic leukemia (CLL), membranous glomerulopathy associated with, fludarabine inducing remission in, 2:E8
Chronic rejection, 150-160
causes of, 157-158
clinical management of, 158-159
diagnosis of, and recommendations on, 151-152
risk factors for, 152-157
Chronic renal diseases (CRDs)
Hantavirus-specific IgG, IgA, IgM, congenital renal diseases versus ARDs and, 734-737
see also specific conditions
Chronic renal failure (CRF)
acute hyperkalemia associated with IV EACA in, 782-785
apolipoprotein(a) phenotypes and Lp(a) concentrations in, 1100-1106
delayed referral of black, Hispanic, and older patients with, 728-733
RAS in, evaluated with Gd-enhanced MRA, 36-42
SCI and, 899-903
see also End-stage renal disease; Fermentable carbohydrates with low-protein diet for CRF *and entries beginning with term*: Uremic
Chronic renal insufficiency (CRI)
aortic dissection in young hypertensive patients with, 374-378
in pregnant patients, 235-237; *see also* Pregnancy in CRI and ESRD patients on CAPD and/or HD
Cimetidine, ANCA-associated acute TIN induced by, 2:E7
Circadian rhythm of natriuresis in nondipper type of essential HTN, 29-35
Citrate anticoagulation, CVVHD with regional, severe hypocalcemia during, 4:E8
Cl (chloride)
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
in SAO, 1149
serum, in Gitelman's syndrome, GH therapy effects on, 779
Clara cell secretory protein (CCSP; uteroglobin; blastokinin) deficiency, lack of Fn accumulation and normal renal function in, 541-551, 598-600
Classification of fermentable carbohydrates, 636
Clearance per unit renal volume (α/V), contrast-enhanced CT measuring fvv and, 754-760, 804-806
Clinical course
of disseminated CCE, 845
of pediatric pulmonary hemorrhage with skin lesions and hematuria, 405-406
after total PTX without autotransplantation for HPT with ESRD, 304-311
see also Progression *and specific conditions*
Clinical features and presentation
of familial IgAN, 861
of HSP, 429
of SLE with HIV infection, 443
see also specific conditions
CLL (chronic lymphocytic leukemia), fludarabine inducing remission in membranous glomerulopathy associated with, 2:E8
Clonidine for pregnant ESRD patients, 242
CMV infection, *see* Cytomegalovirus infection

CN (calcineurin), implications of inhibition of, for chronic rejection, 155
CO_2 (carbon dioxide)
IV EACA effects on, in hyperkalemia, 783
see also PCO_2
Cognitive development of pediatric ESRD patients on HD and/or CAPD, 576
COL4A3 in ECM, CsA toxicity, rejection and, 11-20, 138-139
Collagen
in ECM, CsA toxicity, rejection and, 11-20, 138-139
spiraled and frayed fibrils of type III, in collagenofibrotic glomerulopathy, 123-127
Collagenofibrotic glomerulopathy, as systemic disease, 123-127
Collapsing glomerulopathy (CG), 652-666, 801-803
follow-up on, 652-657, 663
in renal allografts, 658-666
Collecting duct inhibitors, hyperkalemic metabolic acidosis and, 5:xlvii
Color Doppler flow-guided percutaneous ethanol injection therapy (PEIT), prognosis of parathyroid function in ESRD patients on chronic HD after, 1091-1099
Coma due to VPA overdose, 786-789
Common variable immunodeficiency patients, RTx for, 6:E7
Complement, *see* C; C1q nephropathy; C3; C4
Complement receptor 1 (CR1), factor I deficiency and, GN with, 1153-1157
Complete remission of IMGN, prognosis after, 1026-1032
Computed tomography (CT)
contrast-enhanced, α/V and fvv measured with, 754-760, 804-806
spiral, of Ask-Upmark kidney, 4:E4
Congenital renal diseases
Hantavirus-specific IgG, IgA, IgM in ARDs and CRDs versus, 734-737
see also specific conditions
Congestive heart failure (CHF), renal vasodilation due to AA infusion in, enalapril for, 43-51
Continuing medical education, exercises on, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, 304-317, 344-355, 927-940
apolipoprotein(a) phenotypes and Lp(a) concentrations in patients on, 1100-1106
and azotemia-dependent priming of neutrophil oxidative burst, 483-491
Ca balance during pulse alfacalcidol for secondary HPT in patients treated with 1.0 and 1.25 mmol/L Ca dialysate, 82-86
GAGs preventing functional and morphological derangements due to peritoneal fibrosis on, 105-110
HA production by peritoneal cells in patients on, 349-355
hospitalization of patients on, 927-933
with HPT, clinical course after, total PTX without autotransplantation for, 304-311
incidence of acute graft failure with prior, 934-940
increasing serum albumin effects on plasma D-dimer, von Willebrand factor, and platelet aggregation on, 312-317
in pregnant patients, *see* Pregnancy in CRI and ESRD patients on CAPD and/or HD
prognosis of parathyroid function after color Doppler flow-guided PEIT in patients on, 1091-1099
race and urea kinetics with, 325-333
timely initiation of, urea kinetic approach to, 344-348
tolerance of large exchange volumes by patients on, 1136-1141
see also Adequacy of CAPD and/or HD for ESRD; Catheters, CAPD; Core Indicators Project Report on ESRD patients on CAPD and/or CCPD; Diabetic end-stage renal disease, CAPD and/or HD for; Nutrition of ESRD patients on CAPD and/or HD; Outcome of ESRD with CAPD and/or HD; Peritonitis on CAPD; Recombinant human erythropoietin for anemic ESRD patients; Secondary hyperparathyroidism in ESRD patients on CAPD and/or HD; Urea reduction ratio with CAPD and/or HD
Continuous cycling peritoneal dialysis (CCPD) for ESRD
long-term, aquaporin-1 in patients with impaired transcellular water transport on, 383-388
peritoneal transport rates, solute clearance, and mortality with, 523-534
see also Core Indicators Project Report on ESRD patients on CAPD and/or CCPD
Continuous quality improvement (CQI) approach to IDPN, 198-202
Continuous venovenous hemodialfiltration (CVVHD)
meropenem for MOF due to meningococcemia in patient on, pharmacokinetics of, 790-795
with regional citrate anticoagulation, severe hypocalcemia during, 4:E8
Contrast-enhanced computed tomography (CT), α/V and fvv measured with, 754-760, 804-806
Cool dialysate
effects of, on energy balance in HD patients, 1115-1121
effects of midodrine and, on symptomatic intradialytic hypotension, 920-926
Core Indicators Project Report (1996), ESRD, 584-591
Core Indicators Project Report (1997) on ESRD patients on CAPD and/or CCPD
on adequacy of dialysis and nutritional indicators, 6:E3
on iron and rHuEPO therapy, 1187-1189
Coronary artery disease (CAD)
disseminated CCE and, 842
pathogenicity of hyperuricemia in, 229-231
see also Coronary artery disease in ESRD
Coronary artery disease (CAD) in ESRD
DSE to detect, in RTx candidates, 1080-1090
RAS and, 38
and relationship of dialysis membranes to mortality, 5
Coronary heart disease (CHD), disseminated CCE and, 847
Corticosteroids
for disseminated CCE, 840-850, 975-976
high-dose, spontaneous tendon rupture due to ofloxacin therapy of RTx recipients on, 3:E3
see also Steroids
Cost
of IDPN, 198-202
long-term, of steroid-related side effects following RTx, 829-839
Counseling, preconception, of CRI or ESRD patients, 240-241
Course, *see* Clinical course

Coverage decisions, 208-210
CQI (continuous quality improvement) approach to IDPN, 198-202
Cr and CrCl, *see* Creatinine and creatinine clearance
CR1 (complement receptor 1), factor I deficiency and, GN with, 1153-1157
CRDs, *see* Chronic renal diseases
C-reactive protein (CRP), and resistance to rHuEPO, 63-72
Creatinine (Cr) and creatinine clearance (CrCl)
  L-arginine effects on, 1020
  in environmental dRTA, 1182
  in FSGS secondary to hyperfiltration, 54, 55
  in hyporeninemia, 949
  IV EACA effects on, in hyperkalemia, 783
  low-dose ramipril effects on, 453
  and metabolic acidosis in nondiabetic ESRD, 894
  in NIDDM nephropathy, 277, 1066, 1067
  in nondipper type essential HTN, 30
  in normotensive IgAN, effects of ACE inhibitors with losartan on, 852
  in SAO, 1149
  SCI and, 900
  serum, *see* Serum creatinine
  in SLE with HIV infection, 447
  see also Creatinine and creatinine clearance in ESRD patients on CAPD and/or HD; Creatinine and creatinine clearance in MGN
Creatinine (Cr) and creatinine clearance (CrCl) in diabetic ESRD patients on CAPD and/or HD
  with advanced renal failure, 459, 460
  with metabolic acidosis, 894
  in NIDDM nephropathy, 277
Creatinine (Cr) and creatinine clearance (CrCl) in ESRD patients on CAPD and/or HD
  and adequacy of CAPD, 620-621
  with bleach-reprocessed high-flux dialyzers, 90
  or CCPD, mortality and, 525
  hospitalization and, 929
  IDPN effects on, 199
  IPD, APD, and/or TPD, 338-340
  rHuEPO effects on, 1125
  with secondary HPT, IV calcitriol effects on, 75
  see also Creatinine and creatinine clearance in diabetic ESRD patients on CAPD and/or HD; Serum creatinine in ESRD patients on CAPD and/or HD
Creatinine (Cr) and creatinine clearance (CrCl) in MGN, 1027-1029
  and mesangial GN, IFN-α effects on, 1143
Crescentic glomerulonephritis (CGN)
  following ESWL, 128-132
  immune complex-mediated, in renal allograft, MMF for, 552-554
  MPO-ANCA-positive, PSS and, 4:E3
CRF, *see* Chronic renal failure
CRI, *see* Chronic renal insufficiency
Critical-dose drug, defined, 390
CRP (C-reactive protein), and resistance to rHuEPO, 63-72
Cryoglobulin, GN related to, 1:E1
CsA, *see* Cyclosporine
CT, *see* Computed tomography
CV system, *see* Cardiovascular system
CVCs, *see* Central venous catheters, HD
CVVHD, *see* Continuous venovenous hemodialfiltration
Cycling peritoneal dialysis, *see* Continuous cycling peritoneal dialysis for ESRD
Cyclophosphamide, GN treatment with, 1142-1146
Cyclosporine (CsA)
  and acute graft failure with prior HD and/or CAPD, 936
  changes in glomerular hemodynamics induced by, effects of Ca channel blockers on, 262-275
  dose-response of, to diltiazem and verapamil doses, 301-303
  and hyperuricemia, 229
  in pregnancy, 239-240
  RBF autoregulation with postischemic conditions and after treatment with, 4:liv
  see also Cyclosporine, rejection and toxicity of
Cyclosporine (CsA), rejection and toxicity of
  chronic rejection, 153-156
  interstitial ECM changes in allograft associated with, 11-20, 138-139
  and recurrent scleroderma in allograft from identical twin, 4:E7
Cystitis, AM in, 772-777
Cytokines
  in hypercalciuria, 1:xlvi
  in primary GN treatment, 1142-1146
  see also specific cytokines
Cytomegalovirus (CMV) infection
  adipsic hypernatremia with CMV encephalitis and AIDS, 379-382
  in pregnant dialyzed ESRD patients, 244
  in RTx recipient, idiopathic thrombocytopenia after, 6:E6
Cytosolic Ca (calcium), PMNL function impaired by increased, in ESRD, 2:xlv-xlvi

DBP (diastolic blood pressure), *see* Blood pressure
DD/II polymorphism of ACE gene in Chinese NIDDM population, renal function and, 1064-1070
D-dimer, plasma, effects of increasing serum albumin on, in ESRD patients on CAPD, 312-317
Decision making for treatment, framework for, 984-986
Delayed graft function (DGF), prior CAPD and/or HD and, 934-940
Delayed referral for ESRD
  of black, Hispanic, and older patients, 728-733
  consequences of reasons for, S1:4-5
Delivered Kt/V, effects of, on IDPN of dialyzed ESRD patients, 1131-1135
Delivery, *see* Labor and delivery
Demographic characteristics
  of PAs, 648
  relationship between URR, BW and, 584-591
  see also Age; Body mass and body mass index; Body weight; Educational status; Marital status; Race and ethnicity; Sex
Dendritic cells in CaOx nephrolithiasis, 761-771
Dermatan sulphate, heparin with, in GAG mixture to prevent functional and morphological derangements due to peritoneal fibrosis on CAPD, 105-110
DGF (delayed graft function), prior CAPD and/or HD and, 934-940

Diabetes mellitus (DM)
steroid-related posttransplantation, incidence and long-term cost, 829-839
see also Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus nephropathy *and entries beginning with term*: Diabetic
Diabetic end-stage renal disease (ESRD)
and ARAS, 677
fvv and α/V in, 757-758
metabolic acidosis in, 892-898
see also Diabetic end-stage renal disease, CAPD and/or HD for; Diabetic end-stage renal disease, RTx for
Diabetic end-stage renal disease (ESRD), CAPD and/or HD for
adequacy of HD and, 99, 101
or CCPD, double-bag and Y-set disconnect systems and, 536
hospitalization and, 928, 929
HTN control and, 500, 501, 503
IDPN and, 1133
and indications for CAPD catheter tunnel US, 723
intradialytic hypotension and, 922
predialysis BP and mortality with, 507-517, 592-594
preterminal pulmonary thromboembolism and, 706
race and, *see* Diabetic end-stage renal disease, CAPD and/or HD for, race and
RAS and, 38
relationship of dialysis membranes to mortality and, 5
and resistance to rHuEPO, 65
and salvage of nonfunctioning AVF, 913
SCI, proteinuria and, 900, 901
Tenckhoff catheter placement and, 119
Diabetic end-stage renal disease (ESRD), CAPD and/or HD for, race and
age, race, and delayed referral, 729, 730
BMD, bone loss, and race, 942
and CAPD utilization, 326
Diabetic end-stage renal disease (ESRD), RTx for
allograft rejection and, 15, 16
and CG in allograft, 660
HTN following, 24
Diabetic nephropathy
with advanced renal failure, PTF effects on proteinuria and serum TNF-α in, 458-463
Hantavirus-positive serology with, 736
with HPT, total PTX and, 305
see also Diabetic end-stage renal disease; Non-insulin-dependent diabetic nephropathy
Diabetic retinopathy with NIDDM, 1066, 1067
Diagnosis
of chronic rejection, 151-152
pregnancy, in CRI or ESRD women, 241
see also specific diagnostic techniques and conditions
Dialysate
for intensive HD of pregnant ESRD patients, 246-247
1.0 and 1.25 mmol/L Ca, for secondary HPT in ESRD patients on CAPD, on pulse alfacalcidol therapy, Ca balance in, 82-86
temperature of, *see* Cool dialysate
Dialysis centers, outpatient, professional responsibilities of PAs in, 649
Dialysis membranes (dialyzers), *see* Hemodialyzers
Dialysis-related amyloidosis (DRA), cervical spondyloarthropathy with, in ESRD patients on HD, mortality due to, 563-566
Dialysis solutions, PD, in Europe, 3:lii
Dialysis units, role of PAs and nurse practitioners in, 647-651, 796-800
Diastolic blood pressure, *see* Blood pressure
Diazoxide for pregnant ESRD patients, 243
Diet
in hypercalciuria, 1:xlvi-xlvii
in IgAN, 738-745
in prevention of nephrolithiasis, 398-403
see also Nutrition *and entries beginning with term*: Dietary
Dietary protein intake
in ESRD, urea kinetics and, race and, 328; *see also* Dietary protein restriction in ESRD
IgAN and daily, 742
Dietary protein restriction in ESRD
with fermentable carbohydrates, *see* Fermentable carbohydrates with low-protein diet for CRF
metabolic adaptation to, 177-178
Dietary requirements of dialyzed ESRD patients, 176-177
Dietitian, role of renal, in care of pediatric dialysis patients, 578
Diffuse lupus nephritis, intraglomerular monocyte infiltration and immune deposits in, 866-871
1,25-Dihydroxyvitamin D_3 (calcitriol), IV, effects of, on myocardial hypertrophy in ESRD patients on HD with secondary HPT, 73-81
Diltiazem, dose-response of CsA to doses of, 301-303
Discontinuation
of IDPN, 211-216
see also Withdrawal from dialysis
Dissection, aortic, in young hypertensive CRI patients, 374-378
Disseminated (multivisceral) cholesterol crystal embolism (CCE), treatment improving survival with, 840-850, 975-976
Distal renal tubular acidosis (dRTA)
autosomal dominant, 1190-1197
environmental, 1180-1186
U-B PCO_2 and, in SAO, 1147-1152
see also AE1 gene mutation in dRTA
Diuretics
in hyperkalemic metabolic acidosis, 5:xlvii, 5:xlviii
and hyperuricemia, 229
for pregnant ESRD patients, 242
see also specific diuretics
DM, *see* Diabetes mellitus
Dobutamine stress echocardiography (DSE), CAD detection in RTx candidates with, 1080-1090
Dog bite, HUS due to *C canimorsus* bacteremia after, 6:E5
Doppler echography in ESRD patients
for CAD screening, 1083
prognosis of parathyroid function in ESRD patients on chronic HD after color Doppler flow-guided PEIT, 1091-1099
Dose, CAPD and/or HD
actual HD, HEMO Study on, 142-149
CAPD dose and CAPD adequacy, 619
delivered CAPD dose and patient survival, 619-620

relationship between nutrition and CAPD dose, 626
see also Dose, drug
Dose, drug
critical-dose drug, defined, 390
Ferrlecit, *see* Dose, Ferrlecit
of intermittent IP ceftazidime for peritonitis on CAPD, 111-117
low-dose ramipril effects on proteinuria and hyperkalemia, 450-457
meropenem, importance of, 790-795
ofloxacin therapy of RTx recipients on high-dose corticosteroids, spontaneous tendon rupture due to, 3:E3
verapamil and diltiazem, dose-response of CsA to, 301-303
VPA overdose, HD for, 786-789
Dose, Ferrlecit
effects and, 473-474
recommendations on, 480-481
Double-bag disconnect systems, Y-set and, in CAPD, compared, 535-540
Double-lumen catheters, HD, access recirculation secondary to free flow between lumens of, 1168-1170
DRA (dialysis-related amyloidosis), cervical spondyloarthropathy with, in ESRD patients on HD, mortality due to, 563-566
Drinking, *see* Alcohol intake; Beverages
dRTA, *see* Distal renal tubular acidosis
Drug(s)
inhibiting bone resorption, 1:xlvii-xlviii
nephropathy associated with, preterminal pulmonary thromboembolism and, 706
tubular secretory defects due to, hyperkalemic metabolic acidosis and, 5:xlvii
see also Dose, drug; Drug interactions; Drug substitution in immunosuppression *and specific drugs*
Drug interactions between CsA and Ca channel blockers, 301-303
Drug substitution in immunosuppression, 389-397
background to, 390-392
conclusion on, 394-395
rationale for meeting on, 389-390
safe and effective use of generic drugs in, 394
DSE (dobutamine stress echocardiography) to detect CAD in RTx candidates, 1080-1090
Duplex ultrasound (US) of ARAS, 675-781

EACA (epsilon-aminocaproic acid), IV, acute hyperkalemia associated with, in CRF, 782-785
Early stage end-stage renal disease (ESRD), outcome of, in managed care setting, S1:4-9
EC(s) (endothelial cells), activation of, in quinine-induced ITP, 128-132
Echocardiography, dobutamine stress, to detect CAD in RTx candidates, 1080-1090
Echography, *see* Ultrasound
Eclampsia
and hyperuricemia, 229
see also Preeclampsia
ECM (extracellular matrix), changes in allograft interstitial, associated with rejection and CsA toxicity, 11-20, 138-139
Edema with SLE and HIV infection, 443, 447
Education, continuing medical, exercises on, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
Educational status
of ESRD patients, *see* Educational status of ESRD patients on CAPD and/or HD
and IgAN, 739
Educational status of ESRD patients on CAPD and/or HD
double-bag and Y-set disconnect systems and, 536
and preferences for withdrawal from dialysis, 689
Educators, role of, with pediatric dialysis patients, 579
EEG (electroencephalogram), effects of Hct normalization with rHuEPO on, in HD patients, 1122-1130, 1177-1179
EES (extraskeletal Ewing's sarcoma) in transplant recipients, 1164-1167
Effluent chloramphenicol, serum and, to aid in treatment of VRE peritonitis, 3:E4
EG, *see* Ethylene glycol
EKG (electrocardiography), CAD screening with, in ESRD patients, 1083
Elbow crease arteriovenous fistula (AVF), brachiocephalic jump graft fistula as alternative to, 904-909, 977-979
Elderly ESRD patients
on chronic HD, effects of GH therapy on, 709-717
delayed referral of, 728-733
Electrocardiography (EKG), CAD screening with, in ESRD patients, 1083
Electroencephalogram (EEG), effects of Hct normalization with rHuEPO on, in HD patients, 1122-1130, 1177-1179
Electron microscopy (EM)
of CG in renal allografts, 661
of gemcitabine-induced thrombotic microangiopathy, 558
see also specific conditions
Electrophysiology of brain, effects of Hct normalization with rHuEPO on, in HD patients, 1122-1130, 1177-1179
EM, *see* Electron microscopy
Embolism
disseminated cholesterol crystal, treatment improving survival with, 840-850, 975-976
preterminal pulmonary thromboembolism in ESRD patients on HD, rHuEPO and prevalence of, 702-708
Emphysematous pyelonephritis, bilateral, due to *Candida* infection, 2:E10
Employers of PAs, 648
Enalapril for renal vasodilation due to AA infusion in CHF, 43-51
Encephalitis, CMV, adipsic hypernatremia with AIDS and, 379-382
Endothelial cells (ECs), activation of, in quinine-induced ITP, 128-132
Endothelial dysfunction in preeclampsia, 992-997
Endothelin (ET), rHuEPO effects on, HTN and, 823-824
Endothelin-1 (ET-1), lisinopril and molsidomine effects on, in remnant kidney, 749-750
End-stage renal disease (ESRD)
progression to, lisonopril and molsidomine effects on remnant kidney and, 746-753
RAS in, Gd-enhanced MRA of, 36-42
see also Cardiovascular disease with ESRD; Chronic renal failure; Continuous ambulatory peritoneal dialy-

sis for ESRD; Core Indicators Project Report (1996), ESRD; Core Indicators Project Report (1997) on ESRD patients on CAPD and/or CCPD; Delayed referral for ESRD; Diabetic end-stage renal disease; Hemodialysis for ESRD; Hyperparathyroidism in ESRD patients on HD; Hypertensive end-stage renal disease; Medicare; Outcome of ESRD with CAPD and/or HD; Outcome of ESRD in managed care setting; Peritoneal dialysis for ESRD; Pregnancy in CRI and ESRD patients on CAPD and/or HD; Race and ethnicity of ESRD patients on CAPD and/or HD; Recombinant human erythropoietin for anemic ESRD patients; Renal transplantation for ESRD
Energy balance, effects of dialysate temperature on, in HD patients, 1115-1121
Energy malnutrition, *see* Protein-energy malnutrition in dialyzed ESRD patients
Enteral tube feeding of dialyzed ESRD patients, 180-185
Enterococcus peritonitis, vancomycin-resistant, serum and effluent chloramphenicol to aid in treatment of, 3:E4
Enterohepatic cycling of urea and NH_3, relationship between fermentable carbohydrates and, 637-639
Environmental distal renal tubular acidosis (dRTA), 1180-1186
Epidemiology, *see* Incidence; Prevalence
Epinephrine, IV calcitriol effects on, in ESRD patients on HD with secondary HPT, 76, 77
EPO, *see* Erythropoietin
Epsilon (ε)-aminocaproic acid (EACA), IV, acute hyperkalemia associated with, in CRF, 782-785
Equivalence
  population, defined, 390
  therapeutic, defined, 390
Erythrocytes (red blood cells)
  rHuEPO increasing mass of, HTN and, 821-823
  in SLE with HIV infection, 443
Erythropoietin (EPO)
  deficiency in, in hyporeninemia, 947-953
  see also Recombinant human erythropoietin for anemic ESRD patients
ESRD, *see* End-stage renal disease
Essential hypertension (HTN), nondipper type, circadian rhythm of natriuresis in, 29-35
ESWL (extracorporeal shock wave lithotripsy), anti-GBM GN following, 128-132
ET (endothelin), rHuEPO effects on, HTN and, 823-824
ET-1 (endothelin-1), lisinopril and molsidomine effects on, in remnant kidney, 749-750
Ethanol, prognosis of parathyroid function in ESRD patients on chronic HD after color Doppler flow-guided PEIT, 1091-1099
Ethical issues in HEMO Study, 148
Ethnicity, *see* Race and ethnicity
Ethylene glycol (EG)
  CaOx nephrolithiasis induced by, 761-771
  recovery from metabolic acidosis due to poisoning with, 2:E4
Evidence-based medicine
  coverage decisions and, 208-210
  IDPN evaluation and, 186-192
Ewing's sarcoma, extraskeletal, in transplant recipients, 1164-1167
Exchange volumes, tolerance of large, by CAPD patients, 1136-1141
Exit-site infections of CAPD catheters, tunnel ultrasound of, 722-727
Exophthalmos, bilateral ophthalmoplegia and, and CVC placement for HD, 966-969
Extracellular matrix (ECM), changes in allograft interstitial, associated with rejection and CsA toxicity, 11-20, 138-139
Extracellular volume, control of, and adequacy of CAPD, 623
Extracorporeal shock wave lithotripsy (ESWL), anti-GBM GN following, 128-132
Extrarenal arterial aneurysms associated with Ask-Upmark kidney, 4:E4
Extraskeletal Ewing's sarcoma (EES) in transplant recipients, 1164-1167

Fabry's disease, as primary disease, 119
Factor I (C4b/C3b inactivator) deficiency, GN with, 1153-1157
Familial focal segmental glomerulosclerosis (FSGS), sibling RTx for ESRD secondary to, 970-974
Familial IgA nephropathy (IgAN; Berger's disease), 857-865
Fasting glucose in NIDDM nephropathy, 277, 1066
FE, *see* Fractional excretion
Fe, *see* Iron in dialyzed ESRD patients
Fecal excretion of N, *see* Fermentable carbohydrates with low-protein diet for CRF
Fermentable carbohydrates with low-protein diet for CRF, 633-646
  present dietary approach, 634-635
  relationship between fermentable carbohydrates and enterohepatic cycling of urea and NH_3, 637-639
  relationship between fermentable carbohydrates and symbiotic fermentation in large intestine and, 635-637
  and role of fermentable carbohydrates in CRF diet, 639-643
Ferritin
  resistance to rHuEPO and, 63-72
  serum, IV iron dextran and Ferrlecit effects on, compared, 468-470
Ferrlecit (sodium ferric gluconate complex in sucrose) for ESRD patients on HD, IV iron dextran compared with, 464-482, 595-597
Fetal surveillance in dialyzed ESRD patients, 248
FFM (fat-free mass) in elderly chronic HD patients, GH therapy effects on, 713
Fibrillary glomerulonephritis (GN), 2:E1
  Hantavirus-positive serology with, 736
Fibronectin (Fn), CCSP deficiency and lack of renal accumulation of, normal renal function with, 541-551, 598-600
Fibrosis
  interstitial, *see* Interstitial fibrosis
  peritoneal, GAGs preventing functional and morphological derangements due to, on CAPD, 105-110
  spiraled and frayed type III collagen fibrils in collagenofibrotic glomerulopathy, 123-127
  tubulointerstitial, tubular function and, 5:E5, 886-891
Fistula, *see* Arteriovenous fistula

FK506 (tacrolimus) in pregnancy, 240
Fludarabine inducing remission in CLL-associated membranous glomerulopathy, 2:E8
Fn (fibronectin), CCSP deficiency and lack of renal accumulation of, normal renal function with, 541-551, 598-600
Focal segmental glomerulosclerosis (FSGS), 4:E1
  acromegaly-complicated MCNS with, effects of pituitary microsurgery on, 1158-1163
  evolution of BEA-induced papillary necrosis to nephrotic-range proteinuria and, 1033-1039
  Hantavirus-positive serology with, 736
  as primary disease, 305, 338
  proteinuria in, *see* Proteinuria in FSGS
  sibling RTx for ESRD secondary to familial, 970-974
  see also Collapsing glomerulopathy
Folate in ESRD patients on HD and rHuEPO therapy, 493-497
Follow-up
  on CG, 652-657, 663
  on familial IgAN, 861
  long-term, *see* Long-term follow-up
  on proteinuria, 1008-1009
  on refractory graft dysfunction, 1001
  see also Outcome
Fractional excretion (FE)
  of albumin, L-arginine effects on, 1022
  of Na, L-arginine effects on, 1020
  in nephrosis, 5:E5, 886-891
Fractional vascular volume (fvv), contrast-enhanced CT measuring α/V and, 754-760, 804-806
Fractures
  peripheral, incidence and long-term cost of steroid-related, in RTx recipients, 829-839
  vertebral, in ROS, risk factors for, 287-293
Free flow between lumens of double-lumen HD catheters, access recirculation secondary to, 1168-1170
FSGS, *see* Focal segmental glomerulosclerosis
Functional peritoneal derangements, morphological and, on CAPD, due to peritoneal fibrosis, GAGs preventing, 105-110
Furosemide, long-term therapy of healthy population with, and dissociation of glomerular hypertrophy from GS, 1059-1063
fvv (fractional vascular volume), contrast-enhanced CT measuring α/V and, 754-760, 804-806

Gadolinium-enhanced magnetic resonance angiography (Gd-MRA), RAS in CRF evaluated with, 36-42
GAGs (glycosaminoglycans), functional and morphological peritoneal derangements due to peritoneal fibrosis prevented by, on CAPD, 105-110
Gammaglobulin, *see* IgG
Gammopathy, *see* Monoclonal gammopathy
Gastrointestinal ischemia with disseminated CCE, 840-850, 975-976
GBM (glomerular basement membrane), *see entries beginning with terms*: Anti-glomerular basement membrane
Gd-MRA (gadolinium-enhanced magnetic resonance angiography), RAS in CRF evaluated with, 36-42
Gemcitabine, long-term, and thrombotic microangiopathy, 555-562
Gender, *see* Sex
Gene
  p53, overexpression of, in urothelial TCC, 1011-1017, 1171-1173
  Rf-1, linkage analysis of, in black ESRD patients, 294-300
  see also Gene knockout; Mutation; Phenotypes; Polymorphism *and entries beginning with term*: Autosomal
Gene knockout, CCSP, lack of Fn accumulation and normal renal function with CCSP deficiency due to, 541-551, 598-600
Generic drugs
  safe and effective use of, 394
  see also Drug substitution in immunosuppression
Genetics
  of dRTA, 1184
  role of, in hypercalciuria, 1:xlvii
  see also Gene; Sibling renal transplantation for ESRD *entries beginning with terms*: Autosomal, Congenital, Familial, Hereditary *and specific conditions*
Geriatric patients, *see* Elderly ESRD patients
Gestational age, and HD effects on serum progesterone, 918
GFR, *see* Glomerular filtration rate
GH, *see* Growth hormone therapy
Gitelman's syndrome, GH therapy for, 778-781
Globulin, *see specific immunoglobulins*
Glomerular basement membrane, *see entries beginning with terms*: Anti-glomerular basement membrane
Glomerular capillary pressure, effects of Ca channel blockers on CsA-induced changes in, 267-275
Glomerular filtration rate (GFR)
  AA infusion effects on, in CHF, 43-51
  CCSP deficiency effects on, 548
  effects of Ca channel blockers on CsA-induced changes in, 267-275
  in HSP, 429
Glomerular hyperfiltration, *see* Hyperfiltration
Glomerular hypertrophy, long-term furosemide therapy in healthy population and dissociation of GS from, 1059-1063
Glomerulonephritis (GN)
  exacerbation of, following IFN therapy of chronic HCV infection, 1040-1048, 1174-1176
  with factor I deficiency, 1153-1157
  pediatric postinfectious, with hematuria, proteinuria, and HTN, 814-819
  primary, cytokines in treatment, 1142-1146
  see also Glomerulonephritis, as primary disease *and specific types of glomerulonephritis*
Glomerulonephritis (GN), as primary disease
  adequacy of HD and, 99
  chronic, 729, 730, 913
  double-bag and Y-set disconnect systems and, 536
  and HTN control, 500, 501
  in pediatric ESRD, 668
  preterminal pulmonary thromboembolism and, 706
  renal allograft rejection and, 15, 16
  and resistance to rHuEPO, 65
  Tenckhoff catheter placement on CAPD and, 119
Glomerulopathy
  collagenofibrotic, as systemic disease, 123-127

and HTN following RTx, 24
nodular sclerosing, 954-962
see also specific glomerular conditions
Glomerulosclerosis (GS)
long-term furosemide therapy in healthy population, and dissociation of glomerular hypertrophy from, 1059-1063
see also Focal segmental glomerulosclerosis
Glomerulus, *see entries beginning with terms*: Glomerular, Intraglomerular *and element*: Glomerulo-
Glucose
and CCSP deficiency, 548
in NIDDM nephropathy, 277, 1066, 1067
serum, *see* Serum glucose
see also Glucose in ESRD patients
Glucose in ESRD patients
on CCPD, mortality and, 525
control of, as outcome measure in MCOs, S1:14-15
in early stages of disease, S1:7-8
on IPD, APD, and/or TPD, absorption of, 338-340
Glycosaminoglycans (GAGs), functional and morphological peritoneal derangements due to peritoneal fibrosis prevented by, on CAPD, 105-110
GN, *see* Glomerulonephritis
Goodpasture's syndrome, pulmonary hemorrhage and, 404-409
Gossypol in dRTA, 1184
Gout (hyperuricemia), pathogenesis and effects of, in HTN, CV disease, and renal disease, 225-234
Gouty nephropathy, hyperuricemia and, 225-234
Graft failure, incidence of acute, with prior HD and CAPD, compared, 934-940
Graft function
delayed, prior CAPD and/or HD and, 934-940
pregnancy effects on, 238-239
and renal biopsy of refractory graft dysfunction, 998-1003
Graves' disease, MGN with, 369-373
Growth and development
effects of dialysis for maternal ESRD on, 238
of pediatric ESRD patients on CAPD and/or HD, 573
vascular cell, rHuEPO effects on, HTN and, 826-827
see also Growth retardation; Hypertrophy
Growth hormone (GH) therapy
effects of, on elderly chronic HD patients, 709-717
for Gitelman's syndrome, 778-781
Growth retardation
Gitelman's syndrome and, 779
intrauterine, and pediatric BP, 252-260
GS, *see* Glomerulosclerosis

H^+-ATPase (hydrogen-adenosine triphosphatase) in SAO, 1147-1152
H pylori (*Helicobacter pylori*) infection in IgAN, mucosal, systemic Ab response to, 1049-1057
HA (hyaluronan), significance of increased production of, by peritoneal cells in CAPD patients, 318-324
Hantavirus-specific IgG (immunoglobulin G; gamma globulin), IgM, and IgA in ARDs and CRDs versus congenital renal diseases, 734-737
Hb (hemoglobin)
in diabetic nephropathy with advanced renal failure, 460
in HCDD, 959
in NIDDM nephropathy, 1066, 1067
see also Hb in ESRD patients on HD
Hb (hemoglobin) in ESRD patients on HD
folate measurements and, 494
GH therapy effects on, in elderly chronic HD patients, 711
IV iron dextran and Ferrlecit effects on, 473-477
rHuEPO effects on, 1125
HbA1c (hemoglobin A1c)
in diabetic nephropathy with advanced renal failure, 459
in hyporeninemia, 949
in NIDDM nephropathy, 277, 1066, 1067
HBV infection, *see* Hepatitis B virus infection
HCDD (heavy chain deposition disease), 954-962
HCFA (Health Care Financing Administration), *see* Core Indicators Project Report (1996), ESRD; Core Indicators Project Report (1997) on ESRD patients on CAPD and/or CCPD
HCO_3 (bicarbonate)
in Gitelman's syndrome, GH therapy effects on, 779
and metabolic acidosis in diabetic and nondiabetic ESRD, 894, 896
in SAO, 1149
Hct, *see* Hematocrit
HCV infection, *see* Hepatitis C virus infection
HD, *see* Hemodialysis
Health Care Financing Administration, *see* Core Indicators Project Report (1996), ESRD; Core Indicators Project Report (1997) on ESRD patients on CAPD and/or CCPD
Health care personnel
role of, with pediatric ESRD patients on CAPD and/or HD, 577-579
see also Nephrologists; Physician assistants
Health care policy, *see* Advance care planning in dialysis; Medicare
Healthy population
L-arginine inducing microalbuminuria in, 1018-1025
long-term furosemide therapy in, glomerular hypertrophy, GS and, 1059-1063
Heart
collagenofibrotic glomerulopathy effects on, 125
see also Heart failure; Heart rate *and entries beginning with term*: Myocardial *and element*: Card-
Heart disease
coronary, disseminated CCE and, 847
see also Cardiovascular disease with ESRD
Heart failure
congestive, renal vasodilation due to AA infusion in, enalapril for, 43-51
disseminated CCE and, 840-850
Heart rate (HR; pulse)
dialysate temperature and, 1117
with nondipper type essential HTN, 31
see also Heart rate of ESRD patients on HD
Heart rate (HR; pulse) of ESRD patients on HD
IV iron dextran and Ferrlecit effects on, 468
with secondary HPT, effects of IV calcitriol on, 75
Heavy chain deposition disease (HCDD), 954-962
Helicobacter pylori (*H pylori*) infection in IgAN, mucosal, systemic Ab response to, 1049-1057

Hematocrit (Hct)
in CRF, race, age, and delayed referral, 728-733; *see also* Hematocrit in ESRD patients on CAPD and/or HD
in diabetic nephropathy with advanced renal failure, 460
in HCDD, 959
IV EACA effects on, in hyperkalemia, 783
in normotensive IgAN, effects of ACE inhibitors with losartan on, 852
SCI and, 900
Hematocrit (Hct) in ESRD patients on CAPD and/or HD
folate measurements and, 494
hypertensive ESRD, 503
intradialytic hypotension and, 923
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
mortality and, 5
and preterminal pulmonary thromboembolism, 705, 706
and relationship between URR, demographic characteristics, and BW, 589
with secondary HPT, IV calcitriol effects on, 75
see also Hematocrit in ESRD patients on CAPD, HD, and/or PD, rHuEPO and
Hematocrit (Hct) in ESRD patients on CAPD, HD, and/or PD, rHuEPO and
Core Indicators Project Report on rHuEPO effects, 1187-1189
effects of IV iron dextran, Ferrlecit, and rHuEPO, 473-477
HcT normalization with rHuEPO and its effects on brain function, 1122-1130, 1177-1179
and resistance to rHuEPO, 66, 68
Hematuria
with HCDD, 958
with HSP, 429, 435
with IgAN, 435
pediatric pulmonary hemorrhage, skin lesions and, and anti-GBM Abs, 404-409
proteinuria and, *see* Hematuria, proteinuria and
Hematuria, proteinuria and
and HTN in pediatric postinfectious GN, 814-819
nephrotic range proteinuria with hematuria in HIV-infected bisexual male, 607-612
HEMO Study on delivered dialysis dose, 142-149
Hemodialfiltration, *see* Continuous venovenous hemodialfiltration
Hemodialysis (HD)
for ARF with disseminated CCE, 840-850, 975-976
for VPA overdose, 786-789
see also Hemodialysis for ESRD
Hemodialysis (HD) for ESRD
apolipoprotein(a) phenotypes and Lp(a) concentrations in patients on, 1100-1106
and azotemia-dependent priming of neutrophil oxidative burst, 483-491
dialysate temperature and, *see* Cool dialysate
in Europe, 3:l-lii
incidence of acute graft failure in patients on, 934-940
IV Ferrlecit and iron dextran for, compared, 464-482, 595-597
midodrine and cool dialysate effects on intradialytic hypotension, 920-926
persistent SLE and, 872-879
in pregnant patients, *see* Pregnancy in CRI and ESRD patients on CAPD and/or HD
protocol-based intradialytic hypotension treatment in hospitalized HD patients, 1107-1114
ROS on, and risk factors for vertebral fractures, 287-293
timely initiation of, urea kinetic approach to, 344-348
see also Adequacy of CAPD and/or HD for ESRD; Advance care planning in dialysis; Cardiovascular disease in ESRD patients on HD; Chronic hemodialysis for ESRD; Diabetic end-stage renal disease, CAPD and/or HD for; Dose, CAPD and/or HD; Hemodialyzers; Hyperparathyroidism in ESRD patients on HD; Mortality of ESRD patients on CAPD and/or HD; Nutrition of ESRD patients on CAPD and/or HD; Outcome of ESRD with CAPD and/or HD; Race and ethnicity of ESRD patients on CAPD and/or HD; Recombinant human erythropoietin for anemic ESRD patients; Urea reduction ratio with CAPD and/or HD; Vascular access, HD
Hemodialyzers (dialysis membranes; dialyzers)
bleach-reprocessed high-flux, solute and water permeability changes with, 87-96
effects of middle molecule removal and, on chronic HD patient survival, 349-355
β_2-M amyloidosis and, 565
relationship of, to cause-specific mortality, 1-10
Hemodynamic(s)
renal, and microalbuminuria induced by L-arginine in healthy individuals, 1018-1025; *see also* Glomerular filtration rate
see also Blood pressure; Heart rate; Hemodynamic instability
Hemodynamic instability, CV disease and, in ESRD patients on HD, 6:xlix-lii
Hemoglobin, *see* Hb; HbA1c
Hemolytic uremic syndrome (HUS)
due to *Capnocytophaga canimorsus* bacteremia after dog bite, 6:E5
quinine-induced ITP followed by, 133-137
see also Hemolytic uremic, TMA and
Hemolytic uremic syndrome (HUS), TMA and, 555-562
SLE, nephritis and, 1198-1201
Hemorrhage
pediatric pulmonary, with anti-GBM Abs, skin lesions, and hematuria, 404-409
renal, in PAN, 6:E8
vitamin K deficiency and, in RTx and in kidney-pancreas transplantation, 963-965
Henoch-Schönlein purpura (HSP), 427-440
IFN-α- or IFN-β-inducible MxA-proteins in IgAN and, 434-440
pediatric, PP for, 427-433
Heparin
dermatan sulphate and, in GAG mixture to prevent functional and morphological derangements due to peritoneal fibrosis on CAPD, 105-110
and preterminal pulmonary thromboembolism in ESRD patients on HD, 705, 706
Hepatitis B virus (HBV) infection
in SLE patients with HIV infection, 443
see also Hepatitis B virus infection in dialyzed ESRD patients

Hepatitis B virus (HBV) infection in dialyzed ESRD patients
in pregnant patients, 244
protective effects of vaccine against, in chronic HD patients, 356-360
Hepatitis C virus (HCV) infection
IFN therapy of chronic, exacerbation of GN and proteinuria following, 1040-1048, 1174-1176
in pregnant dialyzed ESRD patients, 244-245
in SLE patients with HIV infection, 443
Herbs, Chinese, *see* Interstitial fibrosis, Chinese herb-induced
Hereditary (Southeast Asia) ovalocytosis, dRTA and U-B PCO_2 in, 1147-1152
Herpes simplex virus (HSV) infection in pregnant dialyzed ESRD patients, 244
High-density lipoprotein-cholesterol
in NIDDM nephropathy, 277
see also High-density lipoprotein-cholesterol in ESRD patients on CAPD and/or HD
High-density lipoprotein-cholesterol in ESRD patients on CAPD and/or HD
apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1102
sevelamer hydrochloride and Ca acetate effects on, 699
High-dose corticosteroids, ofloxacin therapy of RTx recipients on, spontaneous tendon rupture due to, 3:E3
High-flux hemodialyzers, bleach-reprocessed, solute and water permeability changes in, 87-96
High-molecular-weight uremic toxins in ESRD, cellular host defense impaired by, 2:xlvi-xlvii
Hip, incidence and long-term cost of steroid-related avascular necrosis of, in RTx recipients, 829-839
Hispanics, *see* Race and ethnicity
Histology and histopathology, renal
in CG, 653
in diffuse LN, 867
in HSP, 429
after IFN therapy of chronic HCV infection, 1042-1044
in IgAN, 1074
see also Renal biopsy
Historical perspectives on drug substitution, 390-392
HIV (human immunodeficiency virus) infection
in bisexual male, nephrotic range proteinuria and hematuria with, 607-612
CG and, 802
SLE with, 441-449
see also AIDS; HIVAN
HIVAN (human immunodeficiency virus-associated nephropathy)
CAPD for, Tenckhoff catheter placement and, 119
as primary disease, 902
and salvage of nonfunctioning AVF, 913
SLE with, 441-449
in Thai population, 282-286
HLA system in familial IgAN, 857-865
H_2O_2 (superoxide), phagocytosis and production of, azotemic plasma effects on, 483-491
Home blood pressure (BP) monitoring for chronic HD patients, 682-687
Home-treated end-stage renal disease (ESRD) patients with IPD, APD and/or TPD, 334-343
Home uterine activity monitoring (HUAM) in pregnant ESRD patients on HD, 917-919
Hospitalization of ESRD patients
on CAPD, 927-933
on HD, protocol-based intradialytic hypotension treatment in, 1107-1114
as outcome measure in MCOs, S1:15
Host defense, *see* Cellular immunity in dialyzed ESRD patients
HPT, *see* Hyperparathyroidism in ESRD patients on HD
HR, *see* Heart rate
HSP, *see* Henoch-Schönlein purpura
HSV (herpes simplex virus) infection in pregnant dialyzed ESRD patients, 244
5-HT (5-hydroxytryptamine; serotonin), and RBF regulation in ARF, 4:lii-liv
HTN, *see* Hypertension
HUAM (home uterine activity monitoring) in pregnant ESRD patients on HD, 917-919
Human immunodeficiency virus, *see* HIV infection; HIVAN
HUS, *see* Hemolytic uremic syndrome, TMA and
Hyaluronan (HA), significance of increased production of, by peritoneal cells in CAPD patients, 318-324
Hydralazine for pregnant ESRD patients, 243
5-Hydroxytryptamine (serotonin; 5-HT), and RBF regulation in ARF, 4:lii-liv
Hypercalciuria, bone loss in, 1:xlvi-xlviii
Hypercholesterolemia, HPT in ESRD patients on HD with hyperphosphatemia and, sevelamer hydrochloride and Ca acetate for, compared, 694-701
Hyperfiltration
FSGS secondary to, lack of hypoalbuminemia with massive proteinuria in, 52-58
and HTN following RTx, 21-28
Hyperkalemia
acute, associated with IV EACA, in CRF, 782-785
low-dose ramipril effects on, 450-457
Hyperkalemic metabolic acidosis, 5:xlv-xlviii
Hypernatremia, adipsic, with AIDS and CMV encephalitis, 379-382
Hyperosmolality in adipsic hypernatremia due to CMV encephalitis and AIDS, 379-382
Hyperoxaluria
adult-onset primary, steroid-responsive pleuropericarditis and livedo reticularis in, 4:E5
in CaOx nephrolithiasis, 761-771
Hyperparathyroidism (HPT) in ESRD patients on HD
clinical course after total PTX without autotransplantation for, 304-311
sevelamer hydrochloride and Ca acetate for hyperphosphatemia and hypercholesterolemia with, compared, 694-701
see also Secondary hyperparathyroidism in ESRD patients on CAPD and/or HD
Hyperphosphatemia, HPT in ESRD patients on HD with hypercholesterolemia and, sevelamer hydrochloride and Ca acetate for, compared, 694-701
Hypertension (HTN)
aortic dissection in young patients with CRI and, 374-378
ARAS and treatment of, 675-681
in CG, 655, 660
disseminated CCE and, 842, 847
in FSGS, 655
in HCDD, 958

hyperuricemia effects in, 225-234
in IgAN, 1073
MCOs and control of, in early stages of ESRD, S1:7; *see also* Hypertensive end-stage renal disease, CAPD and/or HD for
in NIDDM nephropathy, 1066
nondipper type essential, circadian rhythm of natriuresis in, 29-35
post-RTx, *see* Hypertension, post-RTx
proteinuria and, *see* Hypertension, and proteinuria
see also Interdialytic weight gain by ESRD patients, BP and; Recombinant human erythropoietin for anemic ESRD patients on CAPD and/or HD, HTN induced by

Hypertension (HTN), post-RTx
immunologic and nonimmunologic predictors of, 21-28
incidence and long-term cost of steroid-related, 829-839

Hypertension (HTN), and proteinuria
with hematuria, in pediatric postinfectious GN, 814-819
in SCI, 900, 901

Hypertensive end-stage renal disease (ESRD), CAPD and/or HD for
adequacy of CAPD and, 623
adequacy of HD and, 99, 101
double-bag and Y-set disconnect systems and, 536
IDPN and, 1133
inadequate BP control in, 498-506, 592-594
nonfunctioning AVF and, 913
in pregnant patients, management of, 241-243
race, age, delayed referral and, 729, 730
RAS and, 38
and resistance to rHuEPO, 65
salvage of nonfunctioning AVF and, 913
Tenckhoff catheter placement and, 119
see also Recombinant human erythropoietin for anemic ESRD patients on CAPD and/or HD, HTN induced by

Hypertensive nephrosclerosis, 6:E1

Hypertrophy
glomerular, long-term furosemide therapy in healthy subjects and dissociation of GS from, 1059-1063
myocardial, in ESRD patients on HD with secondary HPT, IV calcitriol effects on, 73-81
see also Left ventricular hypertrophy

Hyperuricemia (gout), pathogenesis and effects of, in HTN, CV disease, and renal disease, 225-234

Hypoalbuminemia, and massive proteinuria in FSGS secondary to hyperfiltration, 52-58

Hypocalcemia
in HPT, 304-311
severe, during CVVHD with regional citrate anticoagulation, 4:E8

Hypoplasia, segmental renal, and Ask-Upmark kidney, 4:E4

Hyporeninemia, EPO deficiency in, 947-953

Hypotension
intradialytic, *see* Intradialytic hypotension
predialysis, and mortality of ESRD patients on HD, 507-517, 592-594

ICMCGN (immune complex-mediated crescentic glomerulonephritis) in renal allograft, MMF for, 552-554

I/D polymorphism, *see* Angiotensin-converting enzyme gene, I/D polymorphism of

IDDM, *see* Insulin-dependent diabetes mellitus

Identical twins, recurrent scleroderma in allograft from, 4:E7

Idiopathic membranous glomerulonephritis (IMGN), prognosis after complete remission of, 1026-1032

Idiopathic thrombocytopenia after CMV infection in RTx recipient, 6:E6

IDPN, *see* Intradialytic parenteral nutrition for dialyzed ESRD patients

IDWG, *see* Interdialytic weight gain by ESRD patients, BP and

IF, *see* Immunofluorescence microscopy

IFN, *see* Interferon

Ig (immunoglobulin), monoclonal, in HCDD, 954-962

IgA (immunoglobulin A)
Hantavirus-specific, in ARDs and CRDs versus congenital renal diseases, 734-737
IgA anti-GBM disease with bronchial carcinoma and monoclonal gammopathy, 2:E3

IgA nephropathy (Berger's disease; IgAN), 851-865
Hantavirus-positive serology with, 736
IFN-α- or IFN-β-inducible MxA-proteins in HSP and, 434-440
mucosal *H pylori* infection in, systemic Ab response to, 1049-1057
proteinuria in, effects of ACE inhibitors with losartan on, in normotensive patients, 851-856
risk factors for, 738-745
see also Italian population, IgAN in

IgAN, *see* IgA nephropathy

IGF-1, *see* Insulin-like growth factor-1 in ESRD patients on HD

IgG (immunoglobulin G; gammaglobulin)
Hantavirus-specific, in ARDs and CRDs versus congenital renal diseases, 734-737
in response to mucosal *H pylori* infection in IgAN, 1049-1057

IgM (immunoglobulin M), Hantavirus-specific, in ARDs and CRDs versus congenital renal diseases, 734-737

IMGN (idiopathic membranous glomerulonephritis), prognosis after complete remission of, 1026-1032

Immune complex-mediated crescentic glomerulonephritis (ICMCGN) in renal allograft, MMF for, 552-554

Immune deposits, and intraglomerular monocyte infiltration in diffuse LN, 866-871

Immune response, systemic, to mucosal *H pylori* infection in IgAN, 1049-1057

Immune thrombocytopenic purpura (ITP), quinine-induced, and followed by HUS, 133-137

Immunity, *see* Cellular immunity in dialyzed ESRD patients

Immunodeficiency, RTx for patients with common variable, 6:E7

Immunofluorescence microscopy (IF)
of CG in renal allografts, 661
of gemcitabine-induced thrombotic microangiopathy, 558
in IgAN, 1073
see also specific conditions

Immunoglobulin, *see entries beginning with acronym*: Ig

Immunohistochemistry
of CaOx nephrolithiasis, 761-771

of diffuse LN, 867
of HSP and IgAN, 437
Immunologic predictors of HTN after RTx, 21-28
Immunosuppression
and CG in allograft, 660
and EES in transplant recipients, 1164-1167
in pregnancy, 239-240
role of, in chronic rejection, 153-156
see also Drug substitution in immunosuppression *and specific immunosuppressants; for example*: Cyclosporine; Steroids
IN, *see* Interstitial nephritis
Incidence
of acute graft failure in patients on HD and CAPD, compared, 934-940
of steroid-related side effects following RTx, 829-839
see also Prevalence
Individual bioequivalence, defined, 390
Infants of dialyzed ESRD mothers, management of, 249
Infections
CAPD catheter, *see* Catheters, infected CAPD
neutrophil function and, 2:xlv-xlviii
opportunistic, in pregnant dialyzed ESRD patients, 244-245
pediatric GN with hematuria, proteinuria, and HTN following, 814-819
see also specific infections; for example: Peritonitis on CAPD; Viral infections
Initiation
Ferrlecit therapy, 480
IDPN, 211-216
see also Initiation of HD and/or CAPD
Initiation of HD and/or CAPD
and delayed referral of black, Hispanic, and older CRF patients, 728-733
MCOs and, S1:8
for pediatric ESRD, 568
timely, urea kinetic approach to, 344-348
Injury, *see* Fractures; Renal injury; Spinal cord injury
Insertion/deletion polymorphism, *see* Angiotensin-converting enzyme gene, I/D polymorphism of
Instruction advance directives (ADs), 982
Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
hyporeninemia in, 947-953
see also Diabetes mellitus
Insulin-like growth factor-1 (IGF-1) in ESRD patients on HD
on chronic HD, serum leptin association with weight loss and, 365
serum, as index of malnutrition, 218
Insulin resistance, NIDDM nephropathy with, ACE gene in, 276-281
Intact parathyroid hormone (iPTH)
in Gitelman's syndrome, GH therapy effects on, 779
see also Intact parathyroid hormone in ESRD patients on HD
Intact parathyroid hormone (iPTH) in ESRD patients on HD
and resistance to rHuEPO, 65-68
with secondary HPT, IV calcitriol effects on, 75, 77
serum, *see* Serum intact parathyroid hormone in ESRD patients on HD
Intensive hemodialysis (HD) for ESRD pregnant patients, 246
Interdialytic ambulatory blood pressure monitoring (ABPM), role of, in chronic HD patients, 682-687
Interdialytic weight gain (IDWG) by ESRD patients, BP and ABPM in pediatric patients on chronic HD and, 667-674
inadequate BP control and, 498, 592-594
and predialysis BP, 511-512
Interferon (IFN)
as therapy of chronic HCV infection, exacerbation of GN and proteinuria following, 1040-1048, 1174-1176
see also Interferon-α; Interferon-β
Interferon-α (IFN-α)
IFN-α-inducible MxA-proteins in IgAN and HSP, 434-440
primary GN treatment with, 1142-1146
Interferon-β (IFN-β)-inducible MxA-proteins in IgAN and HSP, 434-440
Interim outcomes for MCOs in early stages of ESRD, S1:5-8
Intermittent intraperitoneal (IP) ceftazidime for peritonitis on CAPD, pharmacokinetics of, 111-117
Intermittent peritoneal dialysis (IPD) for home-treated patients, 334-343
Interstitial expansion, long-term furosemide therapy and, 1059-1063
Interstitial extracellular matrix (ECM), changes in allograft, associated with rejection and CsA toxicity, biopsies of, 11-20, 138-139
Interstitial fibrosis
rejection, CsA toxicity and, 11-20, 138-139
see also Interstitial fibrosis, Chinese herb-induced
Interstitial fibrosis, Chinese herb-induced
and associated with fibrosis of salivary glands, 3:E6
urothelial lesions with, 1011-1017, 1171-1173
Interstitial nephritis (IN)
chronic, Hantavirus-positive serology with, 736
IDPN and, 1133
see also Tubulointerstitial nephritis
Interstitium
CaOx nephrolithiasis effects on cellular composition of, 761-771
see also entries beginning with terms: Interstitial, Tubulointerstitial
Intracellular Ca (calcium), rHuEPO effects on, HTN and, 825
Intradialytic hypotension, 1107-1121
dialysate temperature and, 1115-1121
protocol-based treatment of, in hospitalized HD patients, 1107-1114
symptomatic, midodrine and cool dialysate effects on, 920-926
Intradialytic parenteral nutrition (IDPN) for dialyzed ESRD patients, 186-195, 198-207, 211-220
AA absorption with, 203-204
case for, 194-195
clinical trials in evaluation of, 217-220
CQI approach to, 198-202
effects of, on delivered Kt/V, 1131-1135
evidenced-based evaluation of, 186-192
initiating and discontinuing, 211-216
pediatric experience with, 205-207

Intraglomerular infiltration of monocytes, and immune deposits in diffuse LN, 866-871
Intraperitoneal (IP) ceftazidime, intermittent, for peritonitis on CAPD, pharmacokinetics of, 111-117
Intraperitoneal nutrition (IPN) for dialyzed ESRD patients, 195, 203-204
Intrauterine growth retardation (IUGR), and BP in childhood, 252-260
Intravenous (IV) calcitriol ([1,25-dihydroxyvitamin D_3; 1,25-$(OH_2)D_3$], effects of, on myocardial hypertrophy in ESRD patients on HD with secondary HPT, 73-81
Intravenous (IV) epsilon-aminocaproic acid (IV EACA), acute hyperkalemia associated with, in CRF, 782-785
Intravenous (IV) iron dextran for ESRD patients on HD, safety of Ferrlecit and, compared, 464-482, 595-597
Inulin clearance
  L-arginine effects on, 1020, 1022
  with bleach-reprocessed high-flux dialyzers, 90-92
IP (intraperitoneal) ceftazidime, intermittent, for peritonitis on CAPD, pharmacokinetics of, 111-117
IPD (intermittent peritoneal dialysis) for home-treated patients, 334-343
IPN (intraperitoneal nutrition) for dialyzed ESRD patients, 195, 203-204
iPTH, *see* Intact parathyroid hormone
Iron (Fe) in dialyzed ESRD patients
  anemia and deficiency in, 464-470
  infections and overload of, 2:xlv
  as outcome measure in MCOs, S1:13-14
  in pregnant transplant recipients, 246
Iron (Fe) saturation, IV iron dextran and Ferrlecit effects, 468-470
Iron therapy, *see* Recombinant human erythropoietin for anemic ESRD patients on CAPD, CCPD, and/or HD, iron therapy and
Ischemia
  gastrointestinal, with disseminated CCE, 840-850, 975-976
  renal, ketanserin and RBF autoregulation after CsA treatment and, 4:lii-liii
Italian population, IgAN in
  ACE gene and IgAN progression in, 1071-1079
  familial IgAN, 857-865
ITP (immune thrombocytopenic purpura), quinine-induced, and followed by HUS, 133-137
IUGR (intrauterine growth retardation), and BP in childhood, 252-260
IV, *see entries beginning with term*: Intravenous

Job satisfaction of PAs, 649
Juvenile nephronophthisis (NPH), as primary disease, 305

K (potassium)
  in environmental dRTA, 1181, 1183-1184
  midodrine and cool dialysate effects on, 923
  in normotensive IgAN, effects of ACE inhibitors with losartan on, 852
  in SAO, 1149
  see also Hyperkalemia; Hyperkalemic metabolic acidosis; Plasma K; Serum K
Ketanserin, RBF autoregulation in postischemic conditions and after CsA treatment, 4:liv
Kidney
  Ask-Upmark, renal and extrarenal arterial aneurysms associated with, 4:E4
  collagenofibrotic glomerulopathy effects on, 124-125
  remnant, lisinopril and molsidomine effects on, 746-753
  see also entries beginning with term: Renal *and elements*: Nephr-, Reno-
Kidney-pancreas transplantation, vitamin K deficiency and hemorrhage in RTx and in, 963-965
Kinetics, *see* Kt/V, and CAPD and/or HD for ESRD; Urea kinetic modeling; Urea kinetics
Kt/V, and CAPD and/or HD for ESRD
  delivered, IDPN effects on, 1131-1135
  GH therapy effects on, in elderly chronic HD patients, 711
  in HEMO Study, 144-147
  and hyperphosphatemia, 696
  intradialytic hypotension and, 923
  natural logarithmic estimates of, in pediatric patients, 518-522
  and resistance to rHuEPO, 65-68
  see also Adequacy of CAPD and/or HD for ESRD; Kt/V_{urea}
Kt/V_{urea}
  and relationship of dialysis to mortality, 5
  rHuEPO effects on, 1125
  in RTx recipients, vitamin K deficiency, hemorrhage and, 964
  see also Kt/V_{urea}, and adequacy of CAPD
Kt/V_{urea}, and adequacy of CAPD, 620-621
  nPNA and, 626-627
  nutrition and, 627

Labetalol for pregnant ESRD patients, 242, 243
Labor and delivery
  of ESRD patients on CAPD and/or HD, management of, 248-249
  see also Premature labor in ESRD patients on CAPD and/or HD
Lactate dehydrogenase (LDH)
  and CCSP deficiency, 548
  in ESRD patients on CCPD, mortality and, 525
  IV EACA effects on, in hyperkalemia, 783
Laminin (LM) in ECM, rejection and, 11-20, 138-139
Language, benefit, coverage decisions and, 108
Large exchange volumes, tolerance of, by CAPD patients, 1136-1141
Large intestine, relationship between fermentable carbohydrates and symbiotic fermentation in, 635-637
Latinos, *see* Race and ethnicity
LCDD (light chain deposition disease), 954-962
LDH, *see* Lactate dehydrogenase
Left leg paralysis in RTx recipient, 1:E4
Left ventricular hypertrophy (LVH)
  in primary aldosteronism, 263
  see also Left ventricular hypertrophy in ESRD
Left ventricular hypertrophy (LVH) in ESRD
  adequacy of CAPD and, 623-634
  on HD with secondary HPT, IV calcitriol effects on, 73-81
Leg paralysis, left, in RTx recipient, 1:E4
Leptin, association of serum, with weight loss in ESRD patients on chronic HD, 361-368

Leukemia, chronic lymphocytic, fludarabine inducing remission in membranous glomerulopathy associated with, 2:E8
Leukocytes, *see* White blood cell(s)
Light chain cast nephropathy, and refractory graft dysfunction, 998-1003
Light chain deposition disease (LCDD), 954-962
Light microscopy
of CG in renal allografts, 661
of gemcitabine-induced thrombotic microangiopathy, 558
see also specific conditions
Linkage analysis of *Rf-1* gene in black ESRD patients, 294-300
Lipopolysaccharides (LPSs), effects of, on AM in cystitis, 772-777
Lipoprotein (Lp), metabolism of, in CAPD patients, CAPD adequacy and, 624-625
Lipoprotein(a) [Lp(a)], apolipoprotein(a) phenotypes and concentrations of, in CRF patients, 1100-1106
Lisinopril, effects of molsidomine and, on remnant kidney, 746-753
Lithotripsy, extracorporeal shock wave, anti-GBM GN following, 128-132
Livedo reticularis, steroid-responsive, in adult-onset PH, 4:E5
Liver
collagenofibrotic glomerulopathy effects on, 125
see also Liver failure *and entries beginning with terms*: Enterohepatic, Hepatitis
Liver failure, ARF with, severe hypocalcemia during CVVHD with regional citrate anticoagulation for, 4:E8
Living-related renal transplantation, *see* Sibling renal transplantation for ESRD
Living will, and withdrawal from dialysis, 688-693
LM (laminin) in ECM, rejection and, 11-20, 138-139
LN, *see* Lupus nephritis
Long-term continuous cycling peritoneal dialysis (CCPD), aquaporin-1 in patients with impaired transcellular water transport on, 383-388
Long-term cost of steroid-related side effects following RTx, 829-839
Long-term follow-up
on CAD in ESRD, 1086
on persistent SLE in ESRD, 876
Long-term therapy
with furosemide in healthy subjects, glomerular hypertrophy dissociated from GS and, 1059-1063
with gemcitabine, thrombotic microangiopathy and, 555-562
Loop diuretics, *see* Diuretics
Losartan, effects of ACE inhibitors with, on proteinuria in normotensive IgAN patients, 851-856
Low-density lipoprotein-cholesterol in ESRD patients on CAPD and/or HD
apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1102
sevelamer hydrochloride and Ca acetate effects on, 699
Low-dose ramipril, effects of, on proteinuria and hyperkalemia, 450-457
Low-molecular-weight uremic toxins in ESRD, cellular host defense impaired by, 2:xlvi-xlvii
Low-protein diet, *see* Dietary protein restriction in ESRD
Lp (lipoprotein), metabolism of, in CAPD patients, CAPD adequacy and, 624-625
Lp(a) [lipoprotein(a)], apolipoprotein(a) phenotypes and concentrations of, in CRF patients, 1100-1106
LPSs (lipopolysaccharides), effects of, on AM in cystitis, 772-777
Lungs
anti-GBM Abs in pediatric pulmonary hemorrhage with skin lesions and hematuria, 404-409
collagenofibrotic glomerulopathy effects on, 125
see also Pleuropericarditis; Pneumoperitoneum *and entries beginning with term*: Pulmonary
Lupus nephritis (LN)
diffuse, intraglomerular monocyte infiltration and immune deposits in, 866-871
Hantavirus-positive serology with, 736
as primary disease, 913
see also Systemic lupus erythematosus
LVH, *see* Left ventricular hypertrophy
Lymphoblastoid cells, effects of PKD2 gene mutation in ADPKD on polycystin-2 expression in, 880-885
Lymphocytic leukemia, chronic, fludarabine inducing remission in membranous glomerulopathy associated with, 2:E8

β_2M, *see* β_2-Microglobulin; β_2-Microglobulin amyloids
M235T gene, polymorphism of Atg, and renal function in Chinese NIDDM population, 1064-1079
Macroalbuminuria in NIDDM nephropathy, 1066
Macrophages
in CaOx nephrolithiasis, 761-771
HA production of, in CAPD patients, 318-324
Magnesium, *see* Mg
Magnetic resonance angiography (MRA), Gd-enhanced, RAS in CRF evaluated with, 36-42
Major histocompatibility class II (MHC II) antigen in CaOx nephrolithiasis, 761-771
Malnutrition in ESRD patients on CAPD and/or CCPD
Core Indicators Project Report on indicators, 6:E3
prevalence of, 625
see also Nutrition; Protein-energy malnutrition in dialyzed ESRD patients
Managed care, *see* Outcome of ESRD in managed care setting
Mannitol in treatment of intradialytic hypotension in hospitalized ESRD patients on HD, 1107-1114
MAP (mean arterial pressure), *see* Blood pressure
Marital status of ESRD patients on chronic HD, and preferences for withdrawal from dialysis, 689
Massive proteinuria in FSGS secondary to hyperfiltration, hypoalbuminemia and, 52-58
Maternal complications in CAPD and HD ESRD patients, 238
Mathematical coupling between Kt/V_{urea} and nPNA, CAPD adequacy and, 626-627
MCNS (minimal change nephrotic syndrome), acromegaly-complicated, with FSGS, effects of pituitary microsurgery on, 1158-1163
MCOs (managed care organizations), *see* Outcome of ESRD in managed care setting
Mean arterial pressure, *see* Blood pressure

Medical education, continuing, exercises on, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
Medical ethics, *see* Advance care planning in dialysis
Medicare
and HCFA Core Indicators Project Report, 584-591
and reimbursement for IDPN, 211-216
Membranoproliferative glomerulonephritis (MPGN), Hantavirus-positive serology with, 736
Membranous glomerulonephritis (MGN)
and CG in renal allografts, 660
CLL-associated, fludarabine inducing remission of, 2:E8
Graves' disease with, 369-373
Hantavirus-positive serology with, 736
idiopathic, prognosis after complete remission of, 1026-1032
IDPN and, 1133
IFN-α in treatment of, 1142-1146
Meningitis, meningococcal, MOF in CCVHD patient due to, pharmacokinetics of meropenem for, 790-795
Meningococcemia, MOF in CCVHD patient due to, pharmacokinetics of meropenem for, 790-795
Meropenem for MOF due to meningococcemia in CCVHD patient, pharmacokinetics of, 790-795
Mesangial cells, IFN-α and IFN-β effects on Mx production by, 434-440
Mesangial glomerulonephritis (GN), IFN-α in treatment of, 1142-1146
Mesangiopathy, Hantavirus-positive serology with, 736
Mesothelial cells, HA production in, in CAPD patients, 318-324
Metabolic acidosis
in diabetic and nondiabetic ESRD, 892-898
due to EG poisoning, recovery from, 2:E4
hyperkalemic, 5:xlv-xlviii
Metabolic adaptation to dietary protein restriction, 177-178
α (alpha) Methyldopa for pregnant ESRD patients, 242
Mg (magnesium)
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
serum, in Gitelman's syndrome, GH therapy effects on, 779
MGN, *see* Membranous glomerulonephritis
MHC II (major histocompatibility class II) antigen in CaOx nephrolithiasis, 761-771
Microalbuminuria
L-arginine inducing, in healthy individuals, 1018-1025
in NIDDM nephropathy, 1066
Microangiopathy, *see* Hemolytic uremic syndrome, TMA and
β_2 ($beta_2$)-Microglobulin (β_2M)
L-arginine effects on urinary excretion of, 1022
clearance of, with IPD, APD, and/or TPD, 334-343
β_2-Microglobulin (β_2M) amyloids, cervical spondyloarthropathy with systemic deposits of, in ESRD patients on HD, mortality due to, 563-566
Microorganisms
in peritonitis with double-bag and Y-set disconnect systems, 537
see also specific microorganisms and infections
Microscopy, *see* Electron microscopy; Immunofluorescence microscopy; Light microscopy
Microsurgery, effects of pituitary, on acromegaly-complicated MCNS with FSGS, 1158-1163
Middle molecule removal, effects of hemodialyzers and, on chronic HD patient survival, 349-355
Midodrine, effects of cool dialysate and, on symptomatic intradialytic hypotension, 920-926
Mineralocorticoids in hyperkalemic metabolic acidosis, 5:xlvii-xlviii
Minimal change disease, 3:E1
Minimal change glomerulonephritis (GN), myasthenia gravis and, thymoma with, 5:E4
Minimal change nephrotic syndrome (MCNS), acromegaly-complicated, with FSGS, effects of pituitary microsurgery on, 1158-1163
Minorities, *see* Race and ethnicity
Minoxidil for pregnant ESRD patients, 243
MM, *see* Multiple myeloma
MMF, *see* Mycophenolate mofetil
MOF (multiorgan failure) due to meningococcemia in CCVHD patient, pharmacokinetics of meropenem for, 790-795
Molsidomine, effects of lisinopril and, on remnant kidney, 746-753
Monoclonal gammopathy
IgA anti-GBM disease with bronchial carcinoma and, 2:E3
of undetermined significance, and refractory graft dysfunction, 998-1003
Monoclonal Ig (immunoglobulin) in HCDD, 954-962
Monocytes
intraglomerular infiltration of, and immune deposits in diffuse LN, 866-871
see also Macrophages
Morbidity
on CAPD for ESRD, hospitalization and, 927-933
with primary aldosteronism, 261-266
with SCI, 900
see also Adequacy of CAPD for ESRD, mortality and morbidity in redefinition of *and specific conditions*
Morphological derangements, functional and, due to peritoneal fibrosis on CAPD, GAGs preventing, 105-110
Mortality of ESRD patients on CAPD and/or HD
cause-specific, relationship of hemodialyzers to, 1-10
or CCPD, peritoneal transport rates, solute clearance and, 523-534
due to cervical spondyloarthropathy with systemic β_2M amyloid deposits, 563-566
due to IV iron dextran and Ferrlecit, compared, 468-469
predialysis BP and, 507-517, 592-594
see also Adequacy of CAPD for ESRD, mortality and morbidity in redefinition of
MPGN (membranoproliferative glomerulonephritis), Hantavirus-positive serology with, 736
MPO-ANCA-positive CGN (myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis), PSS and, 4:E3
MRA (magnetic resonance angiography), Gd-enhanced, RAS in CRF evaluated with, 36-42
Mucosal *Helicobacter pylori* (*H pylori*) infection in IgAN, systemic Ab response to, 1049-1057

Multiorgan failure (MOF) due to meningococcemia in CCVHD patient, pharmacokinetics of meropenem for, 790-795
Multiple myeloma (MM)
ARF due to ACE inhibitors and, 2:E5
and refractory graft dysfunction, 998-1003
and salvage of nonfunctioning AVF, 913
Multivisceral (disseminated) cholesterol crystal embolism (CCE), treatment improving survival with, 840-850, 975-976
Muscle strength, effects of GH therapy on, in elderly chronic HD patients, 709-717
Mutation
of PKD2 gene in ADPKD, 880-885
see also: *AE1* gene mutation in dRTA
MxA-proteins, IFN-α- or IFN-β-inducible, in HSP and IgAN, 434-440
Myasthenia gravis, minimal change GN and, thymoma with, 5:E4
Mycophenolate mofetil (MMF)
for ICMCGN in renal allograft, 552-554
in pregnancy, 240
Myeloma, *see* Multiple myeloma
Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis (MPO-ANCA-positive CGN), PSS and, 4:E3
Myocardial hypertrophy in ESRD patients on HD with secondary HPT, IV calcitriol effects on, 73-81
Myoglobin, clearance of, with bleach-reprocessed high-flux dialyzers, 90, 92

N (nitrogen)
balance of, with IPN, 203
fecal excretion of, *see* Fermentable carbohydrates with low-protein diet for CRF
nPCR, nPNA, and CAPD adequacy, 626-627
see also Azotemia; Urea nitrogen
Na (sodium)
L-arginine effects on fractional excretion of, 1020
IV EACA effects on, in hyperkalemia, 783
midodrine and cool dialysate effects on, 923
Na-sensitive HTN with primary aldosteronism, 261-266
reabsorption of, in hyporeninemia, 947-953
in SAO, 1149
urinary excretion of, *see* Urinary excretion, Na
see also Atrial natriuretic peptides in ESRD patients on HD; Hypernatremia
Narrow therapeutic range drug, defined, 390
National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), HEMO Study of, 142-149
National Institutes of Health (NIH), HEMO Study of, 142-149
National Kidney Foundation (NKF), position paper of, on proteinuria, 1004-1010
Natriuresis, *see* Urinary excretion, Na
Natriuretic peptides, *see* Atrial natriuretic peptides in ESRD patients on HD
Natural logarithmic estimates of Kt/V with HD and/or PD for pediatric ESRD, 518-522
Necrosis
avascular hip, following RTx, incidence and long-term cost of steroid-related, 829-839
BEA-induced papillary, evolution of, to FSGS and nephrotic-range proteinuria, 1033-1039
Necrotizing glomerulonephritis (GN), acute, Hantavirus-positive serology with, 736
Neocytolysis, and anemia of ESRD, 59-62
Nephrectomy
donor, pauci-immune RPGN in, 2:E9
lisinopril and molsidomine effects on remnant kidney, 746-753
Nephritis
as primary disease, 305, 729, 730
thrombocytopenic purpura-like syndrome with SLE and, renal biopsy of, 1198-1201
see also specific types of nephritis; for example: Interstitial nephritis; Pyelonephritis
Nephrolithiasis (calculi; kidney stones)
beverages and diet in prevention of, 398-403
CaOx, effects of, on cellular composition of interstitium, 761-771
double-bag and Y-set disconnect systems in CAPD and, 536
Nephrologists
characteristics of, working with PAs or nurse practitioners, 648
pediatric, role of, 577-578
recommendations on CAPD for, 628
Nephrology, role of PAs and nurse practitioners in, 647-651, 796-800
Nephron mass, chronic rejection and, 156-157
Nephronophthisis (NPH), juvenile, as primary disease, 305
Nephrosclerosis, hypertensive, 6:E1
Nephrosis
tubular function and, 886-891, 5:E5
see also Nephrotic syndrome
Nephrotic-range proteinuria
evolution of BEA-induced papillary necrosis to FSGS and, 1033-1039
in FSGS secondary to hyperfiltration, 52-58
hematuria and, in HIV-infected bisexual male, 607-612
see also Nephrotic syndrome
Nephrotic syndrome (NS)
acromegaly-complicated minimal change, with FSGS, effects of pituitary microsurgery on, 1158-1163
Graves' disease and, 369-373
proteinuria in, 1008; *see also* Nephrotic-range proteinuria
strongyloidiasis and, 6:E4
Nephrotoxicity, *see* Cyclosporine, rejection and toxicity of; Poisoning
Neuroectodermal tumor, primitive, EES as, 1164-1167
Neutrophils (polymorphonuclear leukocytes)
function of, and infections in ESRD, 2:xlv-xlviii
RTx correcting azotemia-dependent priming of oxidative burst of, 483-491
see also Antineutrophil cytoplasmic antibodies
NH_3 (ammonia), enterohepatic cycling of, relationship between fermentable carbohydrates and, 637-639
NH_4 (ammonium)
in hyperkalemic metabolic acidosis, 5:xlv-xlviii
production and excretion of, in SAO, 1147-1152
NIDDK (National Institute of Diabetes, Digestive, and Kidney Diseases), HEMO Study of, 142-149

NIDDM, *see* Non-insulin-dependent diabetes mellitus nephropathy
Night calls, PAs on, 648
NIH (National Institutes of Health), HEMO Study of, 142-149
Nitric oxide (NO)
  molsidomine as donor of, effects of lisinopril and, on remnant kidney, 746-753
  rHuEPO effects on, HTN and, 824-825
NKF (National Kidney Foundation), position paper of, on proteinuria, 1004-1010
NO, *see* Nitric oxide
Nodular sclerosing glomerulopathy, 954-962
Nondiabetic end-stage renal disease (ESRD), metabolic acidosis in, 892-898
Nondialysis-related primary and preventive care responsibilities of PAs, 649
Nondipper type essential hypertension (HTN), circadian rhythm of natriuresis in, 29-35
Nonfunctioning arteriovenous fistula (AVF), salvage of, 910-916, 977-979
Nonimmunologic factors
  in chronic rejection, 156-157
  predicting HTN after RTx, 21-28
Non-insulin-dependent diabetes mellitus (NIDDM) nephropathy
  in Chinese population, renal function and polymorphism of ACE DD/II gene and Atg M235T gene in, 1064-1070
  with insulin resistance, I/D polymorphism of ACE gene in, 276-281
Nonoliguric acute renal failure (ARF), post-RTx, 166-169
Norepinephrine, IV calcitriol effects on, in ESRD patients on HD with secondary HPT, 76, 77
Normal renal function, and lack of Fn accumulation with CCSP deficiency, 541-551, 598-600
Normalized protein catabolic rate (nPCR) in ESRD patients on CAPD and/or HD
  and CAPD adequacy, 626
  race and, 327, 329, 330
  and resistance to rhuEPO, 65-68
Normalized protein equivalent of N appearance (nPNA), Kt/V_{urea} and, and CAPD adequacy, 626-627
Normotensive patients with IgAN, effects of ACE inhibitors with losartan on proteinuria in, 851-856
nPCR, *see* Normalized protein catabolic rate in ESRD patients on CAPD and/or HD
NPH (nephronophthisis), juvenile, as primary disease, 305
nPNA (normalized protein equivalent of N appearance), Kt/V_{urea} and, and CAPD adequacy, 626-627
NS, *see* Nephrotic syndrome
Nurse(s), pediatric dialysis, role of, 578
Nurse practitioners, role of, in dialysis units and nephrology, 647-651, 796-800
Nutrition
  in early stages of ESRD, need to assess, S1:6
  see also Diet; Nutrition of ESRD patients on CAPD and/or HD; Parenteral nutrition
Nutrition of ESRD patients on CAPD and/or HD
  and CAPD adequacy, 625-627
  dietary protein intake in, urea kinetics, race and, 328; *see also* Dietary protein restriction in ESRD
  enteral tube, 180-185
  as outcome measure in MCOs, S1:12
  of pregnant patients, 247, 248
  and urea kinetics in black patients on CAPD, 325-333
  see also Dietary protein intake; Dietary protein restriction in ESRD; Malnutrition of ESRD patients on CAPD and/or HD; Nutritional support of dialyzed ESRD patients
Nutritional support of dialyzed ESRD patients, 170-179
  experience with, and opinion on, 221-222
  factors responsible for, 172-179
  introduction to, 170-171
  pediatric, 571-572
  see also Nutritional support of dialyzed ESRD patients, modalities of
Nutritional support of dialyzed ESRD patients, modalities of, 180-185
  association versus causation and, 194
  with IPN, 195, 203-204
  see also Intradialytic parenteral nutrition for dialyzed ESRD patients

Obesity
  and hyperuricemia, 229
  and proteinuria in FSGS secondary to hyperfiltration, 52-58
Obstetric management of dialyzed ESRD patients, 248-249
Obstructive nephropathy, as primary disease, 729, 730
Occupational/physical therapist, role of, with pediatric dialysis patients, 579
Ofloxacin therapy of RTx recipients on high-dose corticosteroids, spontaneous tendon rupture due to, 3:E3
$1\alpha(OH)D_3$ (alfacalcidol), pulse, for secondary HPT in ESRD patients on CAPD treated with 1.0 and 1.25 mmol/L Ca dialysate, Ca balance in, 82-86
$1,25\text{-}(OH_2)D_3$ (calcitriol), IV, effects of, on myocardial hypertrophy in ESRD patients on HD with secondary HPT, 73-81
OKT3 in pregnancy, 240
Older patients, *see* Elderly ESRD patients
Oligonucleotide typing for familial IgAN, 857-865
1.0 mmol/L Ca (calcium) dialysate, Ca balance during pulse alfacalcidol for secondary HPT in ESRD patients on CAPD treated with, 82-86
1.25 mmol/L Ca (calcium) dialysate, Ca balance during pulse alfacalcidol for secondary HPT in ESRD patients on CAPD treated with, 82-86
Ophthalmoplegia, bilateral exophthalmos and, and CVC placement for HD, 966-969
Opportunistic infections in pregnant dialyzed ESRD patients, 244-245
Optimal care of pediatric ESRD patients on HD and/or PD, 567-583
  cognitive development monitoring and, 576
  dialysis prescription and adequacy and, 569-571
  initiation of dialysis and, 568
  modality selection and, 568-569
  nutritional support and, 571-572
  patient growth and development monitoring and, 573
  personnel involved in, 577-579
  psychological adaptation and habilitation and, 577
  and rHuEPO therapy, 575-576

with ROS, 573-575
and RTx, 579-580
school attendance as measure of success of, 576-577
Osmolality in SAO, 1149
Osmoreceptor in adipsic hypernatremia due to CMV encephalitis and AIDS, 379-382
Osteodystrophy, *see* Renal osteodystrophy
Osteoporosis
in ESRD patients on HD, racial differences in, 941-946
incidence and long-term cost of steroid-related, in RTx recipients, 829-839
Outcome
of CG in renal allografts, 660
of Y-TEC peritoneoscopic versus surgical Tenckhoff catheter placement for CAPD, 118-122
see also Follow-up; Outcome of ESRD with CAPD and/or HD; Outcome of ESRD in managed care setting; Patient survival; Prognosis
Outcome of ESRD with CAPD and/or HD
or PD, in Europe, 3:l-lii
in pregnancy, 237-238
see also Mortality of ESRD patients on CAPD and/or HD; Patient survival with ESRD
Outcome of ESRD in managed care setting, S1:1-24
discussion on, S1:20-21
in early stages of disease, S1:4-9
interventions and, at selected MCOs, S1:17-20
introduction to, S1:1-2
measures of, S1:10-16
Outpatient dialysis centers, professional responsibilities of PAs in, 649
Ovalocytosis, Southeast Asia, dRTA and U-B PCO_2 in, 1147-1152
Overdose, VPA, HD for, 786-789
Oxidative burst, azotemia-dependent priming of neutrophil, RTx correcting, 483-491

P (phosphorus) in ESRD patients on CAPD and/or HD
CCPD, mortality and, 525
in pregnant patients, 247
with secondary HPT, IV calcitriol effects on, 75
PCO_2
in Gitelman's syndrome, GH therapy effects on, 779
tension difference in U-B, dRTA and, in SAO, 1147-1152
P53 gene, overexpression of, in urothelial TCC, 1011-1017, 1171-1173
P300 amplitude, effects of Hct normalization with rHuEPO on, in HD patients, 1122-1130, 1177-1179
PA(s) (physician assistants), role of, in dialysis units and nephrology, 647-651, 796-800
PAH (para-aminohippurate) clearance, L-arginine effects on, 1020
PAN (polyarteritis nodosa), renal hemorrhage in, 6:E8
Pancreas, collagenofibrotic glomerulopathy effects on, 125
Pancreas transplantation, kidney-, vitamin K deficiency and hemorrhage in RTx and in, 963-965
Papillary necrosis, BEA-induced, evolution of, to FSGS and nephrotic-range proteinuria, 1033-1039
Para-aminohippurate (PAH) clearance, L-arginine effects on, 1020
PARADE (Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination; NKF position paper), 1004-1010
Paralysis, left leg, in RTx recipient, 1:E4
Parathyroid function, prognosis of, after color Doppler flow-guided PEIT in ESRD patients on chronic HD, 1091-1099
Parathyroid hormone (PTH) in ESRD patients on HD
BMD and bone loss and, 942-944
rHuEPO effects on, 1125
see also Hyperparathyroidism in ESRD patients on HD; Intact parathyroid hormone in ESRD patients on HD
Parathyroidectomy (PTX), total, without autotransplantation for HPT in ESRD, clinical course after, 304-311
Parenteral nutrition
for disseminated CCE, 840-850, 975-976
total, for dialyzed ESRD patients, IDPN compared with, 194-195; *see also* Intradialytic parenteral nutrition for dialyzed ESRD patients
Partial thromboplastin time (PTT), hemorrhage, vitamin K deficiency and, in RTx and in kidney-pancreas transplantation, 963-965
Pathogenesis and pathology, renal
atlas of, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
with CaOx nephrolithiasis, 761-771
and CG in renal allografts, 661
and gemcitabine-induced thrombotic microangiopathy, 558
and hyperuricemia, 225-234
see also Renal diseases
Patient acceptance of CAPD with double-bag and Y-set disconnect systems, 538
Patient characteristics, *see* Demographic characteristics
Patient compliance with immunosuppressive therapy, chronic rejection and, 155-156
Patient survival
with disseminated CCE, treatment improving, 840-850, 975-976
see also Patient survival with ESRD
Patient survival with ESRD
on CCPD, RRF and, 523-534
on chronic HD, effects of middle molecule removal and hemodialyzers on, 349-355
delivered CAPD dose and, 619-620
Patients' preferences for withdrawal from chronic HD, advance care planning to elicit, 688-693
Pauci-immune rapidly progressive glomerulonephritis (RPGN) after donor nephrectomy, 2:E9
PCR, *see* Protein catabolic rate in ESRD patients on CAPD and/or HD
PD, *see* Peritoneal dialysis for ESRD
Pediatric blood pressure (BP), relationship between birthweight and, 253-260
Pediatric dialysis nurses, role of, 578
Pediatric dialysis social worker, role of, 578
Pediatric end-stage renal disease (ESRD), HD and/or PD for chronic HD, ABPM and IDWG in, 667-674
IDPN for APD patients, 205-207
natural logarithmic estimates of Kt/V with, 518-522
optimal care of, *see* Optimal care of pediatric ESRD patients on HD and/or PD
Pediatric glomerulonephritis (GN), postinfectious, with hematuria, proteinuria, and HTN, 814-819

Pediatric Henoch-Schönlein purpura (HSP), PP for, 427-433
Pediatric nephrologists, role of, 577-578
Pediatric pulmonary hemorrhage with skin lesions, hematuria, and anti-GBM Abs, 404-409
Pediatric subspecialists, role of, with pediatric dialysis patients, 579
Pediatric surgeons, role of, with pediatric dialysis patients, 579
PEIT (percutaneous ethanol injection therapy), color Doppler flow-guided, prognosis of parathyroid function in ESRD patients on chronic HD after, 1091-1099
PEM, *see* Protein-energy malnutrition in dialyzed ESRD patients
Penicillium sp:, CAPD catheter infection due to, 3:E5
Pentoxifylline (PTF), effects of, on proteinuria and serum TNF-α in diabetic nephropathy with advanced renal failure, 458-463
Peptic ulcer, pneumoperitoneum due to perforated, in PD patients, 4:E6
Peptides, *see* Atrial natriuretic peptides in ESRD patients on HD
Percutaneous ethanol injection therapy (PEIT), color Doppler flow-guided, prognosis of parathyroid function in ESRD patients on chronic HD after, 1091-1099
Perforated peptic ulcer (PPU) in PD patients, pneumoperitoneum due to, 4:E6
Peripheral fractures, incidence and long-term cost of steroid-related, in RTx recipients, 829-839
Peritoneal cells, significance of increased HA production by, in CAPD patients, 318-324
Peritoneal dialysis (PD) for ESRD
  in Europe, 3:l-lii
  intermittent and/or tidal, for home-treated patients, 334-343
  pneumoperitoneum due to PPU on, 4:E6
  see also Automated peritoneal dialysis for ESRD; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Pediatric end-stage renal disease, HD and/or PD for
Peritoneal fibrosis, GAGs preventing functional and morphological derangements due to, on CAPD, 105-110
Peritoneal permeability on long-term CCPD, 383-388
Peritoneal transport
  characteristics of, and CV mortality on CAPD, 625
  solute clearance and rates of, and mortality with CCPD, 523-534
Peritoneoscopic placement, Y-TEC Tenckhoff catheter, for CAPD, surgical versus, 118-122
Peritonitis on CAPD
  catheter tunnel ultrasound for, 722-727
  double-bag and Y-set disconnect systems and, 535-540
  due to propionibacteria species, 2:E6
  hospitalization and, 927-933
  increased HA production and, 318-324
  intermittent IP ceftazidime for, 111-117
  in pregnant patients, 243
  VRE, serum and effluent chloramphenicol to aid in treatment of, 3:E4
Permeability
  changes in solute and water, with bleach-reprocessed high-flux hemodialyzers, 87-96
  peritoneal, on long-term CCPD, 383-388
Persistent systemic lupus erythematosus (SLE) in RTx recipients or HD patients, 872-879
PG(s) (prostaglandin), rHuEPO effects on, HTN and, 824
PGE_2 (prostaglandin), urinary excretion of, in Gitelman's syndrome, GH therapy effects on, 779
PH (primary hyperoxaluria), adult-onset, steroid-responsive pleuropericarditis and livedo reticularis in, 4:E5
pH
  in Gitelman's syndrome, GH therapy effects on, 779
  in SAO, 1149
Phagocytosis, and H_2O_2 production, azotemic plasma effects on, 483-491
Pharmaceutical equivalents, defined, 390
Pharmacokinetics
  of intermittent IP ceftazidime for peritonitis on CAPD, 111-117
  of meropenem for MOF due to meningococcemia in CCVHD patient, 790-795
  see also specific drugs
Phenotypes, apolipoprotein(a), and Lp(a) concentrations in CRF, 1100-1106
Phosphate (Pi)
  HPT in ESRD patients on HD with hypercholesterolemia and hyperphosphatemia, sevelamer hydrochloride and Ca acetate for, compared, 694-701
  IPD, APD, and/or TPD and, 338-340
Phosphorus, *see* P in ESRD patients on CAPD and/or HD
Physical therapist, role of, with pediatric dialysis patients, 579
Physician assistants (PAs), role of, in dialysis units and nephrology, 647-651, 796-800
Physiology of NH_4 secretion, 5:xlv-xlvi
Pi, *see* Phosphate
Pituitary microsurgery, effects of, on acromegaly-complicated MCNS with FSGS, 1158-1163
PKD, *see* Polycystic kidney disease
PKD2 gene, mutation of, in ADPKD, 880-885
Plasma, azotemic, effects of, on H_2O_2 production and phagocytosis, 483-491
Plasma adrenomedullin (AM) in cystitis, 773-774
Plasma aldosterone
  AA infusion on, in CHF, 46
  in Gitelman's syndrome, GH therapy effects on, 779
  low-dose ramipril effects on, 453
  in primary aldosteronism, 263
Plasma D-dimer, effects of increasing serum albumin on, in ESRD patients on CAPD, 312-317
Plasma flow, *see* Renal plasma flow
Plasma glucose in NIDDM nephropathy, 277
Plasma K (potassium), low-dose ramipril effects on, 453
Plasma proteins in CG and FSGS, 655
Plasma renin activity (PRA)
  AA infusion on, in CHF, 46
  in Gitelman's syndrome, GH therapy effects on, 779
  in hyporeninemia, 949
  IV calcitriol effects on, in ESRD patients on HD with secondary HPT, 77
  low-dose ramipril effects on, 453
  in primary aldosteronism, 263
Plasmapheresis (PP; therapeutic plasma exchange) for pediatric HSP, 427-433

Platelet(s), and preterminal pulmonary thromboembolism, 705, 706
Platelet aggregation, effects of increasing serum albumin on, in ESRD patients on CAPD, 312-317
Pleuropericarditis, steroid-responsive, in adult-onset PH, 4:E5
PMNLs (polymorphonuclear leukocytes), *see* Neutrophils
PNET (primitive neuroectodermal tumor), EES as, 1164-1167
Pneumoperitoneum due to PPU in PD patients, 4:E6
PO_2 (oxygen partial pressure) in Gitelman's syndrome, GH therapy effects on, 779
Poisoning
  EG, recovery from metabolic acidosis due to, 2:E4
  VPA, HD for, 786-789
  see also Cyclosporine, rejection and toxicity of
Polyarteritis nodosa (PAN), renal hemorrhage in, 6:E8
Polyclonal antibodies (Abs) in pregnancy, 240
Polycystic kidney disease (PKD)
  and HTN following RTx, 24
  as primary disease, 119, 305, 536, 913, 1133
  see also Autosomal dominant polycystic kidney disease
Polycystin-2, effects of PKD2 gene mutation in ADPKD on expression of, in lymphoblastoid cells, 880-885
Polymorphism
  RFLP analysis of familial IgAN, 857-865
  see also Angiotensin-converting enzyme gene polymorphism
Polymorphonuclear leukocytes, *see* Neutrophils
Population equivalence, defined, 390
Post-renal transplantation conditions and interventions, *see* Renal transplantation
Potassium, *see* K
PP (plasmapheresis) for pediatric HSP, 427-433
PPU (perforated peptic ulcer), pneumoperitoneum due to, in PD patients, 4:E6
PRA, *see* Plasma renin activity
Prazocin for pregnant ESRD patients, 242-243
Prealbumin in ESRD patients on CAPD and/or HD
  on chronic HD, serum leptin association with weight loss and, 365
  serum, *see* Serum prealbumin in ESRD patients on CAPD and/or HD
Preconception counseling of CRI or ESRD women, 240-241
Predialysis blood pressure (BP), and mortality in diabetic ESRD patients on HD, 507-517, 592-594
Predialysis nutritional state, and outcome of CAPD for ESRD, 625-626
Prednisone
  in pregnancy, 239
  for TIN, 5:E3
Preeclampsia
  endothelial dysfunction in, 992-997
  management of, 243
Pregnancy in CRI and ESRD patients on CAPD and/or HD, 235-252
  Ca and P needs in, 247
  in CRI patients, 235-237
  HD effects on serum progesterone levels in, 917-919
  HUAM of ESRD patients, 917-919
  infections and, 243-245
  management issues with, 240-243
  nutrition in, 247-248
  obstetric management of, 248-249
  and in RTx recipients, 239-240, 245
Premature labor in ESRD patients on CAPD and/or HD
  and HD effects on serum progesterone, 917-919
  management of, 248
Prematurity, and dialysis for maternal ESRD, 238
Pre-renal transplantation (RTx) graft contamination by *Candida*, renal artery rupture secondary to, 1:E3
Prescribability, defined, 390
Prescription, dialysis
  in Europe, 3:l-lii
  HD and/or CAPD, for pediatric ESRD, 569-571
Preterminal pulmonary thromboembolism in ESRD patients on HD, rHuEPO and prevalence of, 702-708
Prevalence
  of malnutrition in ESRD patients on HD, 625
  of preterminal pulmonary thromboembolism in ESRD patients on HD, rHuEPO and, 702-708
  see also Incidence
Prevention
  of CEE recurrence, 844
  of functional and morphological derangements due to peritoneal fibrosis on CAPD with dermatan sulphate and heparin in GAG mixture to prevent, 105-110
  of nephrolithiasis, diet and beverages in, 398-403
  nondialysis-related preventive care responsibilities of PAs, 649
Primary aldosteronism, CV events with, 261-266
Primary care responsibilities, nondialysis-related PA, 649
Primary hyperoxaluria (PH), adult-onset, steroid-responsive pleuropericarditis and livedo reticularis in, 4:E5
Primitive neuroectodermal tumor (PNET), EES as, 1164-1167
Professional responsibilities of PAs in outpatient dialysis centers, 649
Progesterone, serum, in pregnant ESRD patients, HD effects on levels of, 917-919
Prognosis
  after complete remission of IMGN, 1026-1032
  of parathyroid function after color Doppler flow-guided PEIT in ESRD patients on chronic HD, 1091-1099
  see also Outcome
Progression
  of IgAN to renal failure, I/D polymorphism of ACE gene and, 1071-1079
  see also Progressive renal disease; Progressive systemic sclerosis
Progressive renal disease
  evolution of BEA-induced papillary necrosis, to FSGS and nephrotic-range proteinuria, 1033-1039
  lisinopril and molsidomine effects on remnant kidney and, 746-753
  proteinuria in, 1006-1007
  see also Rapidly progressive glomerulonephritis
Progressive systemic sclerosis (PSS)
  MPO-ANCA-positive CGN and, 4:E3
  recurrent, in allograft from identical twin, 4:E7
Propionibacteria species, peritonitis on CAPD due to, 2:E6
Prostaglandin(s) (PG), rHuEPO effects on, HTN and, 824
Prostaglandin E_2 (PGE_2), urinary excretion of, in Gitelman's syndrome, GH therapy effects on, 779

Protein(s)
band 3, *see*: *AE1* gene mutation in dRTA
Bence-Jones, and refractory graft dysfunction, 998-1003
Clara cell secretory, normal renal function and lack of Fn accumulation with deficiency of, 541-551, 598-600
C-reactive, and resistance to rHuEPO, 63-72
dietary, *see entries beginning with terms*: Dietary protein
IFN-α- or IFN-β-inducible MxA-, in HSP and IgAN, 434-440
loss of, with IPD, APD, and/or TPD, 334-343
nPNA, Kt/V_{urea}, and CAPD adequacy, 626, 627
plasma, in CG and FSGS, 655
serum, in normotensive IgAN, effects of ACE inhibitors with losartan on, 852
tubular reabsorption of, and microalbuminuria induced by L-arginine in healthy individuals, 1018-1025
see also Protein catabolic rate in ESRD patients on CAPD and/or HD; Protein-energy malnutrition in dialyzed ESRD patients; Proteinuria
Protein catabolic rate (PCR) in ESRD patients on CAPD and/or HD
on chronic HD, 365, 711, 712
normalized, *see* Normalized protein catabolic rate in ESRD patients on CAPD and/or HD
Protein-energy malnutrition (PEM) in dialyzed ESRD patients
cell-mediated immunity impaired by, 2:xlv
factors responsible for, 172-179
see also Nutritional support of dialyzed ESRD patients
Proteinuria
cardiovascular disease and, 1006
in CG, 655, 660
in diabetic nephropathy with advanced renal failure, PTF effects on, 458-463
exacerbation of, following IFN therapy of chronic HCV infection, 1040-1048, 1174-1176
in FSGS, *see* Proteinuria in FSGS
furosemide effects on, 1060
in HCDD, 958
hematuria and, *see* Hematuria, proteinuria and
and HIV infection, *see* Proteinuria, and HIV infection
in HSP, 429, 435
in IgAN, *see* Proteinuria in IgAN
lisinopril and molsidomine effects on, with remnant kidney, 748
low-dose ramipril effects on, 450-457
in MGN, *see* Proteinuria in MGN
nephrotic-range, *see* Nephrotic-range proteinuria
NKF position paper on, 1004-1010
in primary aldosteronism, 261-266
risk factors for development of, with SCI, 899-903
see also Albuminuria
Proteinuria, and HIV infection
hematuria and nephrotic range proteinuria in bisexual male, 607-612
in HIVAN, 282-286
in SLE, 443, 447
Proteinuria in FSGS, 655
massive, secondary to hyperfiltration, hypoalbuminemia and, 52-58
Proteinuria in IgAN
ACE gene and, 1073
IFN-inducible Mx-proteins and, 435
in normotensive patients, effects of ACE inhibitors with losartan on, 851-856
Proteinuria in MGN, 1027-1029
and mesangial GN, IFN-α effects on, 1143
Prothrombin time (PT), hemorrhage, vitamin K deficiency and, in RTx and in kidney-pancreas transplantation, 963-965
Protocol-based intradialytic hypotension treatment in hospitalized HD patients, 1107-1114
Proxy advance directives (ADs), 982
PSS, *see* Progressive systemic sclerosis
Psychological adaptation of pediatric ESRD patients on CAPD and/or HD, 577
Psychologist/psychiatrist, child, role of, with pediatric dialysis patients, 578-579
Psychosocial issues affecting ESRD patients, adequate handling of, as outcome measure in MCOs, S1:15-16
PT (prothrombin time), hemorrhage, vitamin K deficiency and, in RTx and in kidney-pancreas transplantation, 963-965
PTF (pentoxifylline), effects of, on proteinuria and serum TNF-α in diabetic nephropathy with advanced renal failure, 458-463
PTH, *see* Parathyroid hormone in ESRD patients on HD
PTT (partial thromboplastin time), hemorrhage, vitamin K deficiency and, in RTx and in kidney-pancreas transplantation, 963-965
PTX (parathyroidectomy), total, without autotransplantation for HPT in ESRD, clinical course after, 304-311
Pulmonary hemorrhage, pediatric, with skin lesions, hematuria, and anti-GBM Abs, 404-409
Pulmonary thromboembolism, preterminal, in ESRD patients on HD, rHuEPO and prevalence of, 702-708
Pulse alfacalcidol (vitamin D_3) for secondary HPT in ESRD patients on CAPD treated with 1.0 and 1.25 mmol/L Ca dialysate, Ca balance in, 82-86
Pulse rate, *see* Heart rate
Purpura
Henoch-Schönlein, *see* Henoch-Schönlein purpura
quinine-induced immune thrombocytopenic, followed by HUS, 133-137
thrombocytopenic purpura-like syndrome with SLE and nephritis, renal biopsy of, 1198-1201
Pyelonephritis
bilateral emphysematous, due to *Candida* infection, 2:E10
as primary disease, 305, 706, 913, 1133

Quality improvement, continuous, in IDPN, 198-202
Quality of life of ESRD patients
with double-bag and/or Y-set disconnect systems on CAPD, 538
as outcome measure in MCOs, S1:15-16
Quinine, ITP induced by, and followed by HUS, 133-137

Race and ethnicity
birthweight and BP in childhood and, 254-256
of CG patients, 660
of CRF patients, delayed referral and, 728-733; *see also* Race and ethnicity of ESRD patients on CAPD and/or HD

DD/II polymorphism of ACE gene in Chinese population, renal function and, 1064-1070
dRTA and U-B PCO_2 in SAO, 1147-1152
and hyperuricemia, 229
of SLE patients with HIV infection, 443, 447
see also Italian population, IgAN in; Thai population
Race and ethnicity of ESRD patients on CAPD and/or HD
adequacy of HD and, 99, 101
with CAD, 1083
and CAPD utilization, 325-333
or CCPD, mortality and, 524, 525, 530
differences in BMD and bone loss and, 941-946
hospitalization and, 928, 929
with HTN, 500, 501, 503, 683
hyperphosphatemia and, 696
on IDPN, 1133
with intradialytic hypotension, 922, 1109
IV iron dextran and Ferrlecit effects and, 468
linkage analysis of *Rf-1* gene and, 294-300
of pediatric patients on chronic HD, 668
with peritonitis, intermittent IP ceftazidime therapy and, 115
persistent SLE and, 873
and predialysis BP, 509
with RAS, 38
relationship of dialysis membranes to mortality and, 5
relationship between URR, BW and, 586, 587, 589
and resistance to rHuEPO, 65
Tenckhoff catheter placement and, 119
Radiocephalic fistula, *see* Arteriovenous fistula
Ramipril, effects of low-dose, on proteinuria and hyperkalemia, 450-457
Random effects on adequacy of HD, 97-104
Rapidly progressive glomerulonephritis (RPGN)
pauci-immune, after donor nephrectomy, 2:E9
as primary disease, 305
RAS, *see* Renal artery stenosis
RBCs (red blood cells), *see* Erythrocytes
RBF (renal blood flow), serotonin and regulation of, in ARF, 4:lii-liv
Recirculation, access, secondary to free flow between lumens of dual-lumen HD catheters, 1168-1170
Recombinant human erythropoietin (rHuEPO) for anemic ESRD patients
in early stages of ESRD, S1:6
see also Recombinant human erythropoietin for anemic ESRD patients on CAPD and/or HD
Recombinant human erythropoietin (rHuEPO) for anemic ESRD patients on CAPD, CCPD, and/or HD, iron therapy and
IV Ferrlecit and iron dextran, 464-482, 595-597
in PD patients, Core Indicators Project Report on, 1187-1189
Recombinant human erythropoietin (rHuEPO) for anemic ESRD patients on CAPD and/or HD
folate measurements and, 493-497
iron therapy and, *see* Recombinant human erythropoietin for anemic ESRD patients on CAPD, CCPD, and/or HD, iron therapy and
neocytolysis contribution to anemia and, 59-62
as outcome measure in MCOs, S1:12-14
for pediatric ESRD patients, 575-576
in pregnancy, 246
and prevalence of preterminal pulmonary thromboembolism, 702-708
resistance to, acute-phase response as predictor of, 63-72
see also Hematocrit in ESRD patients on CAPD, HD, and/or PD, rHuEPO and; Recombinant human erythropoietin for anemic ESRD patients on CAPD and/or HD, HTN induced by
Recombinant human erythropoietin (rHuEPO) for anemic ESRD patients on CAPD and/or HD, HTN induced by, 821-828
arginine vasopressin and ANP in, 826
catecholamines and, 823
ET and, 823-824
increased erythrocyte mass and, 821-823
intracellular Ca and, 825
NO and, 824-825
PGs and, 824
renin-angiotensin system and, 823
rHuEPO as direct vasopressor and, 825-826
and rHuEPO effects on vascular cell growth, 826-827
Recombinant human growth hormone, *see* Growth hormone therapy
Recovery from metabolic acidosis due to EG poisoning, 2:E4
Recurrence
of CCE, prevention of, 844
of HPT following total PTX, 304-311
of scleroderma in allograft from identical twin, 4:E7
Red blood cells, *see* Erythrocytes
Referral
delayed, *see* Delayed referral for ESRD
for proteinuria, 1008-1009
Reflux nephropathy
and Ask-Upmark kidney, 4:E4
HPT and, 305
and proteinuria in FSGS secondary to hyperfiltration, 52-58
Refractory graft dysfunction, renal biopsy of, 998-1003
Regional citrate anticoagulation, CVVHD with, severe hypocalcemia during, 4:E8
Reimbursement for IDPN, 211-216
Rejection, *see* Chronic rejection; Cyclosporine, rejection and toxicity of
Remission
of CLL-associated membranous glomerulopathy with fludarabine, 2:E8
complete IMGN, prognosis after, 1026-1032
Remnant kidney, lisinopril and molsidomine effects on, 746-753
Renal artery
aneurysms of, associated with Ask-Upmark kidney, 4:E4
rupture of, secondary to pre-RTx *Candida* contamination of graft, 1:E3
see also Renal artery stenosis
Renal artery stenosis (RAS)
atherosclerotic, and ACE inhibitors for HTN, 675-681
in CRF evaluated with Gd-enhanced MRA, 36-42
Renal biopsy
of allograft interstitial ECM changes associated with rejection and CsA toxicity, 11-20, 138-139
of CG, 653-654

chronic rejection diagnosis with, 152-153
of FSGS secondary to hyperfiltration, 55
of HCDD, 959
of HSP and IgAN, 436
of ICMCGN in renal allograft, MMF for, 552-554
of nephrotic range proteinuria and hematuria in HIV-infected bisexual male, 607-612
of pediatric postinfectious GN with hematuria, proteinuria, and HTN, 814-819
for pediatric pulmonary hemorrhage, skin lesions, and hematuria, 404-409
of post-RTx nonoliguric ARF, 166-169
for refractory graft dysfunction, 998-1003
of SLE with HIV infection, 445, 446
of thrombocytopenic purpura-like syndrome with SLE and nephritis, 1198-1201
see also Histology and histopathology, renal
Renal blood flow (RBF), serotonin and regulation of, in ARF, 4:lii-liv
Renal bone disease
HPT and, 304-311
see also Renal osteodystrophy
Renal dietitian, role in care of pediatric dialysis patients, 578
Renal diseases
acute, chronic, and congenital, Hantavirus-specific IgG, IgM, and IgA in, 734-737
and dRTA, 1184-1185
hyperuricemia and, 225-234
see also Pathogenesis and pathology, renal *and specific conditions*
Renal failure
acute, *see* Acute renal failure
advanced, diabetic nephropathy with, PTF effects on proteinuria and serum TNF-α in, 458-463
chronic, *see* Chronic renal failure; End-stage renal disease
and hyperuricemia, 229
progression of IgAN to, I/D polymorphism of ACE gene and, 1071-1079
Renal failure-1 (*Rf-1*) gene, race and linkage analysis of, 294-300
Renal function
in Chinese NIDDM population, polymorphism of ACE DD/II and Atg M235T genes and, 1064-1079
after IFN therapy of chronic HCV infection, 1042-1044
normal, and lack of Fn accumulation with CCSP deficiency, 541-551, 598-600
residual, *see* Residual renal function
smoking effects on, 807-813
see also Glomerular filtration rate; Renal insufficiency *and specific aspects of renal function*
Renal hemodynamics
and microalbuminuria induced by L-arginine in healthy individuals, 1018-1025
see also Glomerular filtration rate
Renal hemorrhage in PAN, 6:E8
Renal histology, *see* Histology and histopathology, renal
Renal hypoplasia, segmental, and Ask-Upmark kidney, 4:E4
Renal injury, chronic rejection and, 156-157
Renal insufficiency
chronic, *see* Chronic renal insufficiency
primary aldosteronism and, 262
Renal interstitium, *see* Interstitium
Renal ischemia, ketanserin and RBF autoregulation after, 4:lii-liii
Renal mass, reduction of, with massive proteinuria in FSGS secondary to hyperfiltration, 52-58
Renal osteodystrophy (ROS)
risk factors for vertebral fractures in, 287-293
see also Renal osteodystrophy in ESRD
Renal osteodystrophy (ROS) in ESRD
in early stages of ESRD, need to assess and monitor, S1:6-7
management of, as outcome measure in MCOs, S1:14
in pediatric ESRD, care of, 573-575
Renal pathology, *see* Pathogenesis and pathology, renal
Renal plasma flow (RPF)
AA infusion effects on, in CHF, 43-51
in nephrosis, 886-891
Renal replacement therapy (RRT) modality selection
in MCOs, S1:8
for pediatric ESRD, 568-569
see also Hemodialysis for ESRD; Peritoneal dialysis for ESRD; Renal transplantation
Renal segmental hypoplasia, and Ask-Upmark kidney, 4:E4
Renal survival with CG, 654-655
Renal transplantation (RTx)
for CHN, 1011-1017, 1171-1173
see also Renal transplantation for ESRD
Renal transplantation (RTx) for ESRD
azotemia-dependent priming of neutrophil oxidative burst corrected by, 483-491
CG in renal allografts, 658-666
in common variable immunodeficiency patients, 6:E7
DSE to detect CAD in candidates to, 1080-1090
EES in recipients of, 1164-1167
HTN following, *see* Hypertension, post-RTx
idiopathic thrombocytopenia after CMV infection in graft, 6:E6
left leg paralysis in recipient of, 1:E4
and MMF for ICMCGN in renal allograft, 552-554
nonoliguric ARF following, 166-169
ofloxacin therapy of recipients of, on high-dose corticosteroids, spontaneous tendon rupture due to, 3:E3
pediatric, 579-580
persistent SLE in recipients of, 872-879
pregnant recipients of, 239-240, 245; *see also* Pregnancy in CRI and ESRD patients on CAPD and/or HD
recurrent scleroderma in graft from identical twin, 4:E7
rejection of, *see* Chronic rejection; Cyclosporine, rejection and toxicity of
renal artery rupture secondary to pre-RTx *Candida* contamination of graft, 1:E3
sibling, *see* Sibling renal transplantation for ESRD
steroid-related side effects following, incidence and long-term cost of, 829-839
vitamin K deficiency and hemorrhage in kidney-pancreas transplantation and in, 963-965
see also Graft failure; Graft function; Immunosuppression
Renal tubules, *see entries beginning with terms*: Tubular, Tubulointerstitial
Renal vasodilation due to AA infusion in CHF, enalapril for, 43-51
Renal volume, contrast-enhanced CT measuring fvv and clearance per unit, 754-760, 804-806

Renin, *see* Hyporeninemia; Plasma renin activity; Renin-angiotensin system
Renin-angiotensin system, rHuEPO effects on, HTN and, 823
Renovascular disease, as primary disease, 706, 922
Residual renal function (RRF)
  and nutrition on CAPD, 627
  and survival on CCPD, 523-534
Resistance
  to rHuEPO, acute-phase response as predictor of, 63-72
  serum and effluent chloramphenicol to aid in treatment of VRE peritonitis, 3:E4
Restriction fragment length polymorphism (RFLP) analysis of familial IgAN, 857-865
Retinopathy, diabetic, with NIDDM, 1066, 1067
Reused dialyzers
  bleach-reprocessed high-flux, solute and water permeability changes with, 87-96
  relationship of, to ESRD mortality, 5
Rf-1 (renal failure-1) gene, linkage analysis of, race and, 294-300
RFLP (restriction fragment length polymorphism) analysis of familial IgAN, 857-865
RhGH (recombinant human growth hormone), *see* Growth hormone therapy
rHuEPO, *see* Recombinant human erythropoietin for anemic ESRD patients
Rifampin, TIN and minimal self-reexposure to, 5:E3
Risk factor(s)
  for ARAS, 677
  for chronic rejection, 152-157
  for CV disease, *see* Risk factor(s) for CV disease in ESRD
  for IgAN, 738-745
  for β_2-M amyloidosis, 565
  mortality, of ESRD patients on HD, predialysis BP as, 507-517, 592-594
  for proteinuria development with SCI, 899-903
  for vertebral fractures in ROS, 287-293
  see also specific risk factors
Risk factor(s) for CV disease in ESRD
  assessment of, S1:7
  and CAPD adequacy assessment, 621-625
  hyperuricemia as, for HTN and CV disease, 226-227
  management of, as outcome measure in MCOs, S1:14
Ritanserin, effects of, on loss of RBF autoregulation after CsA treatment, 4:liv
ROS, *see* Renal osteodystrophy
RPF, *see* Renal plasma flow
RPGN, *see* Rapidly progressive glomerulonephritis
RRF, *see* Residual renal function
RRT, *see* Renal replacement therapy modality selection
RTx, *see* Renal transplantation
Rupture
  renal artery, secondary to renal graft contamination by *C albicans*, 1:E3
  spontaneous tendon, due to ofloxacin therapy in RTx recipients on high-dose corticosteroids, 3:E3

Safety of IV iron dextran and Ferrlecit for ESRD patients on HD, compared, 464-482, 595-597
Salary of PAs, 648
Saline in treatment of intradialytic hypotension in hospitalized ESRD patients on HD, 1107-1114
Salivary glands, fibrosis of, interstitial fibrosis due to Chinese herbs associated with, 3:E6
Salvage of nonfunctioning AVF, 910-916, 977-979
SAO (Southeast Asia ovalocytosis), dRTA and U-B PCO_2 in, 1147-1152
Sarcoma, extraskeletal Ewing's, in transplant recipients, 1164-1167
SBP (systolic blood pressure), *see* Blood pressure
School attendance, as measure of successful care of pediatric ESRD patients, 576-577
SCI (spinal cord injury), risk factors for development of proteinuria in, 899-903
Scleroderma, *see* Progressive systemic sclerosis
Sclerosing glomerulopathy, nodular, 954-962
Sclerosis, *see* Focal segmental glomerulosclerosis; Progressive systemic sclerosis; Sclerosing glomerulopathy
Secondary hyperparathyroidism (HPT) in ESRD patients on CAPD and/or HD, 73-86
  Ca balance during pulse alfacalcidol for, in patients treated with 1.0 and 1.25 mmol/L Ca dialysate, 82-86
  IV calcitriol effects on myocardial hypertrophy in, 73-81
Secretory protein, Clara cell, normal renal function and, lack of Fn accumulation with deficiency in, 541-551, 598-600
Segmental renal hypoplasia, and Ask-Upmark kidney, 4:E4
Serotonin (5-hydroxytryptamine; 5-HT), and RBF regulation in ARF, 4:lii-liv
Serum albumin
  in FSGS secondary to hyperfiltration, 54, 55
  in HCDD, 958
  race, age, delayed referral and, 729, 730
  in RTx recipients, vitamin K deficiency, hemorrhage and, 964
  SCI and, 900
  in SLE with HIV infection, 443, 447
  see also Serum albumin in ESRD patients on CAPD and/or HD
Serum albumin in ESRD patients on CAPD and/or HD
  apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1101
  on chronic HD, serum leptin association with weight loss and, 365
  effects of increasing, on plasma D-dimer, von Willebrand factor, and platelet aggregation, 312-317
  in elderly chronic HD patients, GH therapy effects on, 709-717
  hyperphosphatemia and, 696
  IDPN and, 214
  as index of malnutrition, 218
  mortality and, 5, 460, 509
  race and, 327-329
  as therapy of intradialytic hypotension in hospitalized ESRD patients on HD, 1107-1114
Serum alkaline phosphatase (ALP) in ESRD patients on HD with ROS, 288-291
Serum angiotensin-converting enzyme (ACE)
  low-dose ramipril effects on, 453
  in NIDDM nephropathy, 1066-1067
Serum C (complement) in SLE with HIV infection, 443, 447

Serum Ca (calcium)
in Gitelman's syndrome, GH therapy effects on, 779
see also Serum Ca in ESRD patients on CAPD and/or HD
Serum Ca (calcium) in ESRD patients on CAPD and/or HD
with ROS, 288, 289
sevelamer hydrochloride and Ca acetate effects on, 698
Serum chloramphenicol, effluent and, to aid in treatment of VRE peritonitis, 3:E4
Serum cholesterol
in FSGS secondary to hyperfiltration, 54
in HCDD, 958
in SLE with HIV infection, 443, 447
Serum Cl (chloride) in Gitelman's syndrome, GH therapy effects on, 779
Serum creatinine (Cr)
in CG, 655, 660
in CRF, delayed referral, age, race and, 728-733; *see also* Serum creatinine in ESRD patients on CAPD and/or HD; Serum creatinine in RTx recipients
in diabetic nephropathy with advanced renal failure, 459, 460
in disseminated CCE, 842, 847
in familial IgAN, 861
in FSGS, 54, 55, 655
in HCDD, 958
HCV infection and, 1041, 1043
in HSP and IgAN, 435
in IgAN, 1073
lisinopril and molsidomine effects on, in remnant kidney, 748
in nondipper type essential HTN, 30
in primary aldosteronism, 263
SCI and, 900
in SLE with HIV infection, 443, 447
Serum creatinine (Cr) in ESRD patients on CAPD and/or HD
as index of malnutrition, 218
and metabolic acidosis in diabetic and nondiabetic ESRD, 894
and relationship of membranes to mortality, 5
Serum creatinine (Cr) in RTx recipients
and post-RTx HTN, 24
with prior HD and/or CAPD, graft failure and, 936
and rejection, *see* Serum creatinine in RTx recipients, rejection and
Serum creatinine (Cr) in RTx recipients, rejection and, 15, 16
chronic rejection, 157-158
Serum ferritin, effects of IV iron dextran and Ferrlecit on, compared, 468-470
Serum glucose
in diabetic nephropathy with advanced renal failure, 459
SCI and, 900
Serum IgA (immunoglobulin A) in IgAN, 1073
Serum insulin-like growth factor-1 (IGF-1) in ESRD, as index of malnutrition, 218
Serum intact parathyroid hormone (iPTH) in ESRD patients on HD
with ROS, 288, 289
sevelamer hydrochloride and Ca acetate effects on, 698
Serum K (potassium)
in environmental dRTA, 1181
in Gitelman's syndrome, GH therapy effects on, 779
in primary aldosteronism, 263
Serum leptin, association of, with weight loss in ESRD patients on chronic HD, 361-368
Serum Mg (magnesium) in Gitelman's syndrome, GH therapy effects on, 779
Serum Na (sodium) in Gitelman's syndrome, GH therapy effects on, 779
Serum P (phosphorus) in ESRD patients on HD
with ROS, 288, 289
sevelamer hydrochloride and Ca acetate effects on, 698
Serum parathyroid hormone (PTH) in ESRD patients
apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1101
on CAPD with secondary HPT, pulse alfacalcidol effects on, 84
with ROS on chronic HD, pulse alfacalcidol effects on, 288-290
Serum prealbumin in ESRD
apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1101
as index of malnutrition, 218
Serum progesterone in pregnant ESRD patients, HD effects on levels of, 917-919
Serum protein in normotensive IgAN, effects of ACE inhibitors with losartan on, 852
Serum transferrin in ESRD, as index of malnutrition, 218
Serum triglycerides in FSGS secondary to hyperfiltration, 54
Serum tumor necrosis factor-α (TNF-α) in diabetic nephropathy with advanced renal failure, PTF effects on, 458-463
Serum urea in diabetic ESRD, 460, 894
Serum urea nitrogen, GH therapy effects on, in elderly chronic HD patients, 711
Sevelamer hydrochloride, Ca acetate and, for HPT with hyperphosphatemia and hypercholesterolemia in ESRD patients on HD, compared with, 694-701
Severe hypocalcemia during CVVHD with regional citrate anticoagulation, 4:E8
Sex
and ARAS, 677
birthweight and BP in childhood and, 254-256
of CG patients, 660
of CHF patients, 44
of diabetic nephropathy patients, *see* Sex of diabetic nephropathy patients
of ESRD patients, *see* Sex of ESRD patients on CAPD and/or HD; Sex of RTx recipients
of familial IgAN patients, 861
of FSGS patients, 54, 55
fvv, α/V and, 757-758
of HCDD patients, 958
of HCV infection patients, 1041
of HIV-infected patients, *see* Sex of HIV-infected patients
of HSP patients, 429, 435
of hyporeninemic patients, 949
of IgAN patients, 435, 739, 1073
of MGN patients, 372, 1027-1029
of nondipper type essential HTN patients, 30
of primary aldosteronism patients, 262, 263
Sex of diabetic nephropathy patients
with advanced renal failure, 459
of NIDDM nephropathy patients, 277, 1066, 1067

Sex of ESRD patients on CAPD and/or HD
adequacy of HD and, 99, 101
apolipoprotein(a), phenotypes Lp(a) concentrations and, 1101
with CAD, 1083
and CAPD use, 326
or CCPD, mortality and, 524, 525, 530
ceftazidime therapy and, 115
on chronic HD, *see* Sex of ESRD patients on chronic HD
delayed referral and, 729, 730
double-bag and Y-set disconnect systems and, 536
effects of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation and, 313
of elderly chronic HD patients, GH therapy effects and, 711
hospitalization and, 928, 929
with HPT, 305, 696
hypertensive ESRD, 503
on IDPN, 1133
intradialytic hypotension and, 922, 1109
and IV iron dextran and Ferrlecit effects, 468
persistent SLE and, 873
and predialysis BP, 509
and preterminal pulmonary thromboembolism, 706
with RAS, 38
relationship of dialysis membranes to mortality and, 5
and relationship between URR, demographic characteristics, and BW, 586, 587, 589
and resistance to rHuEPO, 65
Tenckhoff catheter placement and, 119
Sex of ESRD patients on chronic HD
home BP monitoring and, 683
pediatric patients, 668
and preferences for withdrawal from dialysis, 689
Sex of HIV-infected patients
HIV-infected bisexual male with nephrotic range proteinuria and hematuria in, 607-612
with SLE, 443, 447
Sex of RTx recipients
and post-RTx HTN, 24, 25
prior HD and/or CAPD and graft failure, 936
vitamin K deficiency, hemorrhage and, 964
SGA (small-for-gestational-age) infants, and BP in childhood, 253-260
Shock wave lithotripsy, extracorporeal, anti-GBM GN following, 128-132
Short stature, Gitelman's syndrome and, GH therapy for, 778-781
SIADH (syndrome of inappropriate antidiuretic hormone secretion), 161-165
Sibling renal transplantation (RTx) for ESRD
and recurrent scleroderma in graft from identical twin, 4:E7
secondary to familial FSGS, 970-974
Side effects
of anticoagulants, disseminated CCE as, 840-850, 975-976
steroid-related, following RTx, incidence and long-term cost of, 829-839
Skin lesions, pediatric pulmonary hemorrhage, hematuria and, and anti-GBM Abs, 404-409
SLE, *see* Systemic lupus erythematosus
Small-for-gestational-age (SGA) infants, and childhood BP, 253-260
Small solutes, clearance of, with IPD, APD, and/or TPD, 334-343
Smoking
and ARAS, 677
and CHN, 1013
and disseminated CCE, 842
and ESRD mortality, 5, 509
and IgAN, 741
renal function effects of, 807-813
Social worker, pediatric dialysis, role of, 578
Sodium, *see* Na
Sodium ferric gluconate complex in sucrose (Ferrlecit) for ESRD patients on HD, safety of IV iron dextran and, compared, 464-482, 595-597
Solute(s)
changes in permeability of water and, with bleach-reprocessed high-flux hemodialyzers, 87-96
see also Solute clearance
Solute clearance
in assessing CAPD adequacy, 618-621
peritoneal transport rates and, and mortality with CCPD for ESRD, 523-534
of small solutes, with IPD, APD, and/or TPD, 334-343
Sonography, *see* Ultrasound
Southeast Asia ovalocytosis (SAO), dRTA and U-B PCO_2 in, 1147-1152
Spinal cord injury (SCI), risk factors for development of proteinuria in, 899-903
Spiral computed tomography (CT) of Ask-Upmark kidney, 4:E4
Spleen, collagenofibrotic glomerulopathy effects on, 125
Spondyloarthropathy, cervical, with systemic β_2M amyloid deposits in ESRD patients on HD, mortality due to, 563-566
Spontaneous tendon rupture due to ofloxacin therapy in RTx recipients on high-dose corticosteroids, 3:E3
Standard hemodialysis (HD) dose in HEMO Study, 145-146
Stenosis, *see* Renal artery stenosis
Steroids
incidence and long-term cost of side effects of, following RTx, 829-839
pleuropericarditis and livedo reticularis responsive to, in adult-onset PH, 4:E5
primary GN treatment with, 1142-1146
see also Corticosteroids; Mineralocorticoids
Stones, *see* Nephrolithiasis
Stress echocardiography, dobutamine, to detect CAD in RTx candidates, 1080-1090
Stroke, and primary aldosteronism, 261-266
Strongyloidiasis, NS and, 6:E4
Substitution, drug, *see* Drug substitution in immunosuppression
Superoxide (H_2O_2), phagocytosis and production of, azotemic plasma effects on, 483-491
Supplementation
vitamin, and IgAN, 741
see also Diet
Surgeons, pediatric, role of, with pediatric dialysis patients, 579

Surgery
pituitary microsurgery for acromegaly-complicated MCNS with FSGS, 1158-1163
for Tenckhoff catheter placement, Y-TEC peritoneoscopic placement compared with, 118-122
vascular, disseminated CCE as, 840-850, 975-976
see also Nephrectomy; Parathyroidectomy; Renal transplantation
Survival
renal, with CG, 654-655
see also Patient survival with ESRD
Switchability, defined, 390
Symbiotic fermentation in large intestine, relationship between fermentable carbohydrates and, 635-637
Symptomatic intradialytic hypotension, effects of cool dialysate and midodrine on, 920-926
Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 161-165
Synthetic dialysis membranes, relationship of, to cause-specific mortality, 1-10
Systemic antibody (Ab) response to mucosal *H pylori* infection in IgAN, 1049-1057
Systemic disease, collagenofibrotic glomerulopathy as, 123-127
Systemic lupus erythematosus (SLE)
HIV with, 441-449
persistent, in RTx recipients or HD patients, 872-879
as primary disease, 119, 660, 729, 730
thrombocytopenic purpura-like syndrome with nephritis and, renal biopsy of, 1198-1201
see also Lupus nephritis
Systemic manifestations of SLE with HIV infection, 443, 447
Systemic β_2-microglobulin (β_2M) amyloids, cervical spondyloarthropathy with deposits of, in ESRD patients on HD, mortality due to, 563-566
Systemic sclerosis, *see* Progressive systemic sclerosis
Systolic blood pressure, *see* Blood pressure

Tacrolimus (FK506) in pregnancy, 240
TCC (transitional cell carcinoma), CHN and, 1011-1017, 1171-1173
Technology, coverage decisions and assessment of, 208-210
Temperature, dialysate, *see* Cool dialysate
Temporary hemodialysis (HD) vascular access, 718-721
Tenckhoff catheter for CAPD, surgical versus Y-TEC peritoneoscopic placement of, 118-122
Tendon rupture, spontaneous, due to ofloxacin therapy in RTx recipients on high-dose corticosteroids, 3:E3
Thai population
environmental dRTA in, 1180-1186
HIVAN in, 282-286
Therapeutic equivalence, defined, 390
Therapeutic plasma exchange (TPE; plasmapheresis) for pediatric HSP, 427-433
Therapy and management, *see specific conditions and therapeutic modalities*
Thiazide diuretics, *see* Diuretics
Thrombocytopenia, idiopathic, after CMV infection in RTx recipient, 6:E6
Thrombocytopenic purpura, quinine-induced immune, followed by HUS, 133-137
Thrombocytopenic purpura-like syndrome with SLE and nephritis, renal biopsy of, 1198-1201
Thromboembolism, preterminal pulmonary, in ESRD patients on HD, rHuEPO and prevalence of, 702-708
Thromboplastin time, partial, hemorrhage, vitamin K deficiency and, in RTx and in kidney-pancreas transplantation, 963-965
Thrombotic microangiopathy, *see* Hemolytic uremic syndrome, TMA and
Thymoma with myasthenia gravis and minimal change GN, 5:E4
Thyroid gland, collagenofibrotic glomerulopathy effects on, 125
Thyroiditis, autoimmune, MGN and, 369-373
Tidal peritoneal dialysis (TPD) for home-treated patients, 334-343
Time on CAPD and/or HD
and CAD screening with DSE, 1083
on chronic HD, and preferences for withdrawal from dialysis, 689
effects of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation and, 313
hospitalization and, 928
HPT and, 305, 696
for hypertensive ESRD, 500
for pediatric ESRD, 668
preterminal pulmonary thromboembolism and, 706
and racial differences in BMD and bone loss, 942
and relationship between URR, demographic characteristics, and BW, 588, 589
and resistance to rHuEPO, 65-67
and ROS, 288, 289
and tolerance of large exchange volumes, 1137
urea kinetics, nutrition and, 330
Timely initiation of HD and/or CAPD, urea kinetic approach to, 344-348
TIN, *see* Tubulointerstitial nephritis
TMA (thrombotic microangiopathy), *see* Hemolytic uremic syndrome, TMA and
TNF-α (tumor necrosis factor-α), serum, in diabetic nephropathy with advanced renal failure, PTF effects on, 458-463
Tolerance of large exchange volumes by CAPD patients, 1136-1141
Tomography, *see* Computed tomography
Total cholesterol
in ESRD on CAPD and/or HD, apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1102
in NIDDM nephropathy, 277
sevelamer hydrochloride and Ca acetate effects on, in HD patients, 699
Total parathyroidectomy (PTX) without autotransplantation for HPT in ESRD, clinical course after, 304-311
Total parenteral nutrition (TPN) for dialyzed ESRD patients, IDPN compared with, 194-195
Toxicity, *see* Cyclosporine, rejection and toxicity of; Poisoning; Toxins
Toxins, low- and high-molecular-weight uremic, in ESRD, cellular host defense impaired by, 2:xlvi-xlvii
Toxoplasmosis in pregnant dialyzed ESRD patients, 244

TPD (tidal peritoneal dialysis) for home-treated patients, 334-343
TPE (therapeutic plasma exchange; plasmapheresis) for pediatric HSP, 427-433
TPN (total parenteral nutrition) for dialyzed ESRD patients, IDPN compared with, 194-195
Transcellular water transport in long-term CCPD patients, aquaporin-1 and impaired, 383-388
Transferrin in ESRD
  resistance to rHuEPO and, 63-72
  serum level of, as index of malnutrition, 218
Transitional cell carcinoma (TCC), CHN and, 1011-1017, 1171-1173
Transplantation, *see* Autotransplantation; Renal transplantation
Triglycerides
  apolipoprotein(a) phenotypes, Lp(a) concentrations and, 1102
  in NIDDM nephropathy, 277, 1066, 1067
  serum, in FSGS secondary to hyperfiltration, 54
  sevelamer hydrochloride and Ca acetate effects on, in HD patients, 699
Tubular acidosis, *see* Distal renal tubular acidosis
Tubular defects, secretory, in hyperkalemic metabolic acidosis, 5:xlvii
Tubular function, and tubulointerstitial fibrosis, 886-891, 5:E5
Tubular protein reabsorption, and microalbuminuria induced by L-arginine in healthy individuals, 1018-1025
Tubulointerstitial fibrosis, tubular function and, 886-891, 5:E5
Tubulointerstitial nephritis (TIN)
  ANCA-associated acute, induced by cimetidine, 2:E7
  and minimal self-reexposure to rifampin, 5:E3
  as primary disease, 24
Tumor necrosis factor-α (TNF-α), serum, in diabetic nephropathy with advanced renal failure, PTF effects on, 458-463
Twin, identical, recurrent scleroderma in allograft from, 4:E7
Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus nephropathy
Type III collagen fibrils, spiraled and frayed, in collagenofibrotic glomerulopathy, 123-127

U-B PCO_2 (urine minus blood carbon dioxide tension difference), dRTA and, in SAO, 1147-1152
UG (uteroglobin; Clara cell secretory protein; blastokinin) deficiency, lack of Fn accumulation and normal renal function with, 541-551, 598-600
UKM, *see* Urea kinetic modeling
Ulcer, pneumoperitoneum due to perforated peptic, in PD patients, 4:E6
Ultrafiltration
  dialysate temperature and, 1117
  effects of Ca channel blockers on CsA-induced changes in coefficient of, 267-275
  with impaired transcellular water transport on long-term CCPD, 383-388
  with IPD, APD, and/or TPD, 334-343
Ultrasound (US)
  of CAPD catheter tunnel, indications for, 722-727
  DSE to detect CAD in RTx candidates, 1080-1090
  duplex, of ARAS, 675-781
  see also Doppler echography in ESRD patients
Urea
  clearance of, with bleach-reprocessed high-flux dialyzers, 90
  enterohepatic cycling of, relationship between fermentable carbohydrates and, 637-639
  in MGN and mesangial GN, IFN-α effects on, 1143
  see also Serum urea; Urea kinetic modeling; Urea kinetics
Urea kinetic modeling (UKM)
  of IDPN effects on delivered Kt/V, 1131-1135
  Kt/V estimation in pediatric ESRD patients with, 518-522
Urea kinetics
  as approach to timely initiation of HD and/or CAPD, 344-348
  on CAPD, nutrition, race and, 325-333
  see also Kt/V, and CAPD and/or HD for ESRD
Urea nitrogen
  blood, *see* BUN in ESRD
  GH therapy effects on, in elderly chronic HD patients, 711, 712
  IPD, APD, and/or TPD and, 338-340
Urea reduction ratio (URR) with CAPD and/or HD
  center and random effects on variability of, 97-104
  IDPN effects on, 199
  as measure of dialysis dose, 147-148
  relationship between demographic characteristics, BW and, 584-591
Uremia, *see* Chronic renal failure; End-stage renal disease
Uremic syndrome, *see* Hemolytic uremic syndrome, TMA
Uremic toxins in ESRD, low- and high-molecular-weight, cellular host defense impaired by, 2:xlvi-xlvii
Uric acid, and metabolic acidosis in diabetic and nondiabetic ESRD, 894
Urinary excretion
  AM, in cystitis, 772-777
  Ca, in Gitelman's syndrome, GH therapy effects on, 779
  glucose, in hyporeninemia, 949
  K, in environmental dRTA, 1181
  NH_4, in SAO, 1147-1152
  vanadium, in environmental dRTA, 1182
  see also Urinary excretion, Na *and entries beginning with suffix*: -uria
Urinary excretion, Na
  with CHF, 44, 47, 48
  circadian rhythm of, in nondipper type essential HTN, 29-35
  low-dose ramipril effects on, 453
Urine minus blood carbon dioxide tension difference (U-B PCO_2), dRTA and, in SAO, 1147-1152
Urologic malignancy, CHN and, 1011-1017, 1171-1173
Urothelial lesions in CHN, 1011-1017, 1171-1173
URR, *see* Urea reduction ratio with CAPD and/or HD
US, *see* Ultrasound
Uterine activity monitoring, home, in pregnant ESRD patients on HD, 917-919
Uteroglobin (UG; Clara cell secretory protein; blastokinin) deficiency, lack of Fn accumulation and normal renal function with, 541-551, 598-600

α/V (clearance per unit renal volume), contrast-enhanced CT measuring fvv and, 754-760, 804-806
Vaccination, HBV, for chronic HD patients, 356-360
Valproic acid (VPA), HD for overdose of, 786-789
Vanadium, and environmental dRTA, 1180-1186
Vancomycin clearance with bleach-reprocessed high-flux dialyzers, 90-92
Vancomycin-resistant enterococcus (VRE) peritonitis, serum and effluent chloramphenicol to aid in treatment of, 3:E4
Vascular access, *see* Catheters, CAPD; Vascular access, HD
Vascular access, HD
  as outcome measure, S1:10-11
  and preterminal pulmonary thromboembolism, 706
  see also Arteriovenous fistula; Catheters, HD
Vascular cell growth, rHuEPO effects on, HTN and, 826-827
Vascular surgery for disseminated CCE, 840-850, 975-976
Vascular volume, fractional, contrast-enhanced CT measuring α/V and, 754-760, 804-806
Vasculitis, pediatric pulmonary hemorrhage and, 404-409
Vasodilation, renal, due to AA infusion in CHF, enalapril for, 43-51
Vasopressin, *see* Antidiuretic hormone; Arginine vasopressin
Ventricular hypertrophy, *see* Left ventricular hypertrophy
Verapamil, dose-response of CsA to doses of, 301-303
Vertebral fractures in ROS, risk factors for, 287-293
Viral infections
  IgAN, HSP and, 434-440
  see also specific viral infections
Vitamin B_{12}, effects of hemodialyzers on clearance of, 349-355
Vitamin D_3 and analogues, *see* Alfacalcidol; Calcitriol
Vitamin K deficiency, and hemorrhage in RTx and in kidney-pancreas transplantation, 963-965
Von Willebrand factor (vWF), effects of increasing serum albumin on, in ESRD patients on CAPD, 312-317
VPA (valproic acid), HD for overdose of, 786-789
VRE (vancomycin-resistant enterococcus) peritonitis, serum and effluent chloramphenicol to aid in treatment of, 3:E4
vWF (von Willebrand factor), effects of increasing serum albumin on, in ESRD patients on CAPD, 312-317

Water permeability, changes in solute and, with bleach-reprocessed high-flux hemodialyzers, 87-96
Water transport, transcellular, on long-term CCPD, aquaporin-1 in patients with impaired, 383-388
WBCs, *see* White blood cell(s); White blood cell count
Weight gain, *see* Interdialytic weight gain by ESRD patients, BP and
Weight loss by ESRD patients on chronic HD, serum leptin associated with, 361-368
White Americans, *see* Race and ethnicity
White blood cell(s) (WBCs; leukocytes)
  MxA-protein levels in, in HSP and IgAN, 436-437
  in SLE with HIV infection, 443
  see also Macrophages; Monocytes; Neutrophils; White blood cell count
White blood cell (WBC) count
  in ESRD patients on CCPD, mortality and, 525
  in HCDD, 959
Withdrawal from dialysis, 601-606
  from chronic HD, advance care planning to elicit patients' preferences for, 688-693
Work site of PAs, 648-649
Work week of PAs, 648

Xylitol, CaOx nephrolithiasis and, 761-771

Y-set disconnect systems, double-bag and, in CAPD, compared, 535-540
Y-TEC peritoneoscopic placement of Tenckhoff catheter for CAPD with surgical versus, 118-122